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INTRODUCTION 
             Stomach cancer is the fourth most common cancer worldwide 
(1).
 It 
is a disease with a high death rate (~700,000 per year) making it the 
second most common cause of cancer death worldwide after lung 
cancer
(2).
 It is more common in men than in women with a ratio of 1.6:1
(1, 
3)
. It is a disease of middle aged and elderly with a peak incidence at 
around 65 years 
(1)
. Although a steady decline in the incidence of gastric 
carcinoma has been noted worldwide, the absolute number of new cases 
per year is increasing mainly because of the aging population. Decline in 
incidence rate is seen in the western countries 
(4)
. In Asia it is still one of 
the most common malignancies accounting for 18% of all malignancies. 
In countries like Japan and Korea it accounts for 56% of malignancies
 (5)
. 
More than 50% of cases present in advanced unresectable stages 
making cure impossible. The overall 5 year survival rate is 28% 
irrespective of the stage at which the patient presents. The morphological 
and histological types of gastric carcinomas are  variable and they may not 
correlate well with the prognosis. The prognosis is mainly dependant on 
the clinical stage of the disease. But even within a specific stage, there is 
variability in prognosis from patient to patient. There has been a constant 
search for specific biological markers to identify the subgroups of patients 
with more aggressive course of the disease 
(6)
. E Cadherin, EGFR, p53 and 
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HER-2/Neu have been proposed as potential tool for the evaluation of 
prognosis of gastric cancer 
(7, 8, 9, 10)
. 
E Cadherin plays a crucial role in cell- cell adhesion in epithelial 
tissues. The decreased E Cadherin expression correlates with 
dedifferentiation, infiltrative tumour growth, distant metastasis, and poor 
survival for patients with certain carcinomas 
(7)
. 
 Epidermal Growth Factor Receptor (EGFR) is a transmembrane 
tyrosine kinase receptor, and is one of the members of EGFR family of 
receptors. This receptor activation causes stimulation of the downstream 
signaling pathway that regulates cell proliferation, migration, adhesion, 
differentiation and survival. Gene amplification and ⁄ or protein over 
expression of EGFR have been observed in a variety of solid tumours 
(8)
. 
 p53 is a tumour suppressor gene which negatively regulates cell 
cycle. A loss of function mutation in p53 gene results in enhanced 
proliferative activity and tumour progression. In contrast to the normal 
p53 protein, the mutated p53 protein has an increased half-life and hence 
accumulates within the cell nucleus. This can be detected 
immunohistochemically using monoclonal antibodies 
(9)
. 
 HER-2/Neu, also known as c-Erb-2, encodes a transmembrane 
tyrosine kinase receptor; homologous to epidermal growth factor receptor 
2
.The protein encoded by this gene is suggested to be a growth factor 
receptor involved in the growth and progression of malignant cells 
(10)
. 
 Despite many studies that have been conducted in gastric 
carcinoma worldwide for the expression of E Cadherin, EGFR, p53 and 
HER-2/Neu and for their prognostic importance, the results are still 
contradictory. Some found a statistically significant association of these 
markers with prognosis and survival, while others found no such 
association. In a related development, targeted therapy against EGFR and 
HER-2/Neu has attracted much attention recently. Hence accurate 
evaluation of expression of EGFR and HER-2/Neu proteins might help to 
identify eligible candidates for new targeted therapy.  
 In this study, an attempt is made to study the expression of these 
four markers in gastric carcinoma immunohistochemically and compare it 
with various clinicopathological parameters and to study their prognostic 
significance. 
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AIMS AND OBJECTIVES 
1. To study the incidence and distribution of gastric carcinoma in 
patients who attended Rajiv Gandhi Government General Hospital, 
during January to December 2011. 
2. To study the various clinicopathological factors of gastric 
carcinoma including age of incidence, sex preponderance, tumour 
location, tumour size, gross appearance, depth of infiltration, 
lymphovascular invasion and perineural invasion. 
3. To determine the immunohistochemical expression of E Cadherin, 
EGFR, p53 and HER-2/Neu in Gastric carcinoma. 
4. To study the association of  E Cadherin, EGFR, p53 and HER-
2/Neu in Gastric carcinoma with known prognostic factors like age, 
sex, tumour size, histological type, grade, depth of infiltration, 
lymphovascular invasion, lymphocytic response. 
5. To study the prognostic significance of E Cadherin, EGFR, p53 and 
HER-2/Neu in Gastric carcinoma and its association with survival. 
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REVIEW OF LITERATURE 
            Gastric carcinoma is a malignant neoplasm arising from the glandular 
epithelial lining of stomach mucosa. The benign and malignant gastric ulcers 
were first described by J.Cruveilhier, in 1835 
(11)
. The first successful 
operation, a subtotal resection with gastroduodenal anastomosis, was 
performed on 1881, by Theodor Billroth in Vienna. The specimen showed 
Gastric cancer involving the distal part of the stomach with all regional nodal 
involvement 
(13)
. The patient died of recurrence after 4 months of surgery. 
Sixteen years later, in 1897, first successful total gastrectomy was performed 
by Karl Schlatter in Zurich 
(12)
. 
 Subsequently during the late nineteenth and twentieth centuries and 
now, in the early twenty-first century, millions of patients have been 
recognized to be affected by gastric cancer and submitted to surgery.  
Epidemiology: 
The incidence of gastric cancer between countries shows 
considerable variation. Over 934,000 cases are diagnosed each year 
(1)
. 
Japan and Korea have the highest gastric cancer rates in the world 
(14, 15)
. 
In Japan, the age-standardized incidence rates are 69.2 per 100,000 in 
men and 28.6 per 100,000 in women 
(16)
. In India, there is a wide variation 
in the incidence of gastric carcinoma. According to the study conducted 
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by the National Cancer Registry Programme of India in 2001, the number 
of new gastric cancer cases were estimated to be approximately 35,675 
(23,785 in men; 11,890 in women)
(17)
. The incidence rate of gastric cancer 
was four times higher in Southern India compared with Northern India
(18)
. 
Among the six registries in Southern India, the highest incidence in both 
sexes was reported from Chennai. The age-standardized incidence rates in 
Chennai are 13.6 per 100,000 in men and 6.5 per 100,000 in women
(17)
. 
The rates in rural population were much lower than those in the urban 
population. Early gastric cancer has a higher five year survival rate (up to 
95%) than those of advanced gastric cancer (10% -20%)
(19)
. 
Clinical Presentation: 
Early gastric cancers are usually asymptomatic. Advanced gastric 
cancers have non-specific symptoms like dysphagia, vomiting or 
regurgitation, epigastric distress or pain, hematemesis, melena, anorexia, 
weight loss and fatigue. Usually proximal gastric cancer causes dysphagia 
and distal gastric cancer causes gastric outlet obstruction. 
Etiopathogenesis: 
 Gastric carcinogenesis is a multistep and multifactorial process. 
Progression from normal gastric mucosa through chronic gastritis, 
atrophic gastritis with or without intestinal metaplasia to dysphagia and to 
carcinoma is seen in many cases
(20)
.
   
The risk factors associated with 
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gastric carcinoma include chronic intestinal metaplasia and atrophic 
gastritis, Helicobacter pylori infection, dietary factors like food rich in 
salt & nitrates (dried and salted fish) and low in micronutrients/ 
antioxidants (vitamin C), smoking, pernicious anaemia, previous history 
of gastric surgery having gastric stumps, Menetrier‘s disease and peptic 
ulcer disease
(22)
. First-degree relatives of affected patients are at three 
times risk for developing the disease when compared to the general 
population. 
 Helicobacter pylori infection: 
Three independent prospective cohort studies showed 
epidemiological evidence of strong association with H Pyroli infection. 
Patients with gastric carcinoma had anti H Pyroli antibodies detectable in 
their serum stored 10 or more years before the diagnosis of cancer.
(23,24,25)
. 
At the pathogenesis level H Pylori has been shown to induce phenotypic 
changes such as mucosal atrophy, intestinal metaplasia and dysplasia, 
leading to the development of adenocarcinoma.
(26)  
The development of 
severe gastritis with atrophy and intestinal metaplasia is particularly 
associated with infection by CagA-positive strains of the bacillus
(27,28)
 .  
The various mechanisms proposed are increased epithelial cell 
proliferation with a resultant increased risk of mutations
(29)
, bacterial 
overgrowth with increased potential to generate intraluminal 
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carcinogens
(30)
, increased free radicals
(31)
 and reduced gastric antioxidant 
levels
(32)
. 
 Diet: 
Most consistent association with dietary factor is observed in 
intestinal type of gastric carcinoma. Fresh fruits and vegetables lower the 
risk due to the antioxidant actions of ascorbic acid, carotenoids, folates, 
tocopherols
(33,34)
. Salt intake, smoked foods, pickled vegetables, chilli 
pepper are found to be associated with high risk
(35,36,37)
. 
Bile reflux: 
The relative risk of adenocarcinoma is on a rise in the gastric stump 
of patients who have undergone previous gastric surgery 5 to 10 years 
ago. The risk is especially high in Bilrotth II operation which increases 
the risk of bile reflux
(38,39)
. 
Host factors: 
 There is evidence that germline truncating mutations in the gene 
for E Cadherin, a calcium-dependent cell adhesion protein, are 
responsible for a rare autosomal dominant inherited form of gastric 
carcinoma in young persons. This condition is characterized by multiple 
tumours of diffuse or signet ring cell histological types that do not arise in 
a background of intestinal metaplasia
(40)
. Affected family members can be 
identified by mutation-specific genetic testing and offered prophylactic 
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gastrectomy
(41)
. Patients with hereditary non-polyposis colorectal cancer 
(HNPCC), which results from germline mutation of one of the DNA 
mismatch repair genes hMLH1, hMSH2, hMSH6, hPMS1 and hPMS2 
also have an increased frequency of gastric cancers
(42)
. Peutz– Jegher‘s 
syndrome also shows an increased risk of gastric cancer
(43)
. 
Anatomical Distribution of Gastric Carcinoma:             
 Gastric carcinoma that arises from the distal part (antro-pyloric 
region and lesser curvature) is more common than those arising from the 
proximal part (body and cardia). In the past decade there is a considerable 
increase in the incidence of cancer of the cardia and this is being 
attributable to widespread use of endoscopy and improvements in 
diagnostic methods. Proximal carcinomas are more aggressive than the 
distal gastric carcinomas. 
Early gastric cancer: 
 Gastric carcinoma confined to mucosa and submucosa, with or 
without lymph nodal metastasis is defined as early gastric cancer. The 
term ‗early‘ implies the disease is potentially curable and not the early 
stage in the genesis of the tumour
(55)
. Usually they are asymptomatic. 
Most frequently reported symptoms are epigastric pain and dyspepsia, 
occurring within few months before diagnosis
(45)
. 
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      Most of these lesions are small (2 to 5cms), typically located in lesser 
curvature around antropyloric region. Multiple primary sites are seen in 3 
to 13% of cases and are associated with bad prognosis
(46)
.
 
          Based on endoscopic appearance, three types of Early gastric 
carcinomas are identified: 
 Type I  : protruding 
 Type II : Superficial- II A- elevated 
                                 - II B- flat 
                                 - II C- depressed 
 Type III :Excavating 
       
 
                    Figure 1: Classification of early gastric cancer based on endoscopic appearance 
 Type II is more frequent (80%) of which type II C is the most common 
one. 
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 Microscopic variants include ―minute gastric cancer‖(less than 5 
mm)
(46) 
 and ―Superficial spreading type‖ which shows serpiginous ulcers 
with neoplastic cells that spread laterally over large surface area of 
mucosa. 
       Elevated lesions are usually well differentiated and intestinal type, 
flat lesions and depressed ones are usually poorly differentiated, intestinal 
or diffuse types.
(47-49)
 Lymph node involvement occurs in 10 – 20% of all 
cases
(46,47,50)
. 63% cumulative risk of progression to advanced gastric 
cancer is seen in untreated cases
(51)
. 5 year survival rate in surgically 
resected cases is more than 90%
(52,53)
. Recurrence rate is 5 to 15%
(54)
. 
Advanced Gastric Carcinoma: 
 When the tumour invades beyond submucosa of stomach wall, it is 
called as advanced gastric carcinoma. It implies that resection and cure of 
the tumour is difficult and does not indicate that the tumour is of higher 
stage. 
 Based on gross appearance, Dr.R.Borrman gave the following 
classification. 
Type I   – Polypoid / Nodular 
Type II  – Ulcerative, localized / Fungating 
Type III – Ulcerative, infiltrative 
Type IV – Diffusely infiltrative (linitis plastica) 
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 Figure 2: Borrman’s Classification based on gross appearance 
 Ulcerated tumours occur most frequently in the antrum, on the 
lesser curve. The ulcers are large with irregular margins, raised rolled out 
edges, necrotic shaggy base
(56)
. Polypoid, nodular and fungating tumours 
usually occur in the body of the stomach in the region of the greater 
curvature, or fundus. Infiltrative cancers spread superficially, producing 
plaque-like lesions. It is usually accompanied by thickening of the entire 
stomach wall producing the so-called linitis plastica (leather bottle) 
stomach. Many gastric carcinomas secrete considerable amounts of mucin 
and give the gelatinous appearance of colloid carcinomas. 
Microscopic appearance: 
 Several classifications based on the histological picture exist for 
gastric carcinoma. A few of the commonly used ones are the following. 
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 Lauren’s classification: (1965)(57) 
The histological classification of Lauren divides gastric 
adenocarcinoma into two main types - Intestinal and Diffuse. Tumours 
with approximately equal quantities of intestinal and diffuse components 
are called indeterminate/unclassified carcinomas. Also, carcinomas too 
undifferentiated to fit neatly into either category are placed in the 
indeterminate/ unclassified category.
 
 Of the 1344 tumours initially described by Lauren, 53% were 
intestinal type, 33% were diffuse type, and the rest were indeterminate/ 
unclassified type.
(57) 
Intestinal carcinoma: 
They have a glandular pattern usually accompanied by tubules, 
papillary formation or solid components. The glands range from well 
differentiated to moderately differentiated grade, sometimes with poorly 
differentiated picture. The glandular epithelium consists of pleomorphic 
cells with large hyperchromatic nuclei often with numerous mitoses. The 
adjacent gastric mucosa often shows chronic gastritis, intestinal 
metaplasia and sometimes dysplasia. It is common in the elderly and in 
males. 
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 Diffuse carcinoma: 
 These are predominantly composed of poorly cohesive and 
diffusely infiltrating small tumour cells having indistinct cytoplasm and 
hyperchromatic nuclei. Glandular pattern may be seen in the more 
superficial part of the tumour. Signet ring cells are common along with 
extracellular mucin in the stroma. Desmoplasia is more pronounced and 
generally there is no accompanying dysplasia or metaplasia. They 
commonly occur at a younger age and shows equal sex incidence. 
Classification of Mulligan and Rember (1975)
(58)
: 
This classification expands Lauren‘s classification by adding a 
third type - pylorocardiac gland carcinoma
(58)
. Pylorocardiac gland 
carcinomas commonly present as well demarcated tumours. They are 
commoner in men and microscopically show varying sized glands with 
tubular or papillary pattern containing cells that often show striking 
vacuolation or clear cell change that stain brilliantly with periodic acid–
Schiff reaction. 
Ming’s Classification (1977)(59): 
This classification divides gastric adenocarcinomas into two types - 
Expanding type and Infiltrating type
(59)
. The expanding type has pushing 
edges and forms discrete tumour nodules. This compares roughly to the 
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intestinal type of Lauren and occurs in patients over 50 years of age. The 
infiltrative type is ill defined, contains widely infiltrative tumour cells 
with poor inflammatory cell response and collagenous stroma. It is more 
common under the age of 50. 
WHO Classification (1990)
 (60)
:       
WHO classification of Gastric tumours is given in Annexure II. 
Based on the predominant histological picture, gastric adenocarcinoma is 
classified as the following types.  
Tubular adenocarcinoma : 
 It is composed predominantly of neoplastic tubules, showing 
irregular branching and anastomosis, surrounded by fibrous stroma. 
Individual tumour cells are cuboidal, columnar or flattened by 
intraluminal mucin. Cytological atypia varies from low to high-grade. A 
poorly differentiated variant called solid carcinoma is also seen. An 
oncocytic variant of tubular adenocarcinoma has also been described
(61)
. 
Papillary adenocarcinoma: 
 These show well-differentiated picture with elongated finger-like 
processes lined by cuboidal cells and central fibro-vascular connective 
tissue cores. Some cases show tubular differentiation (papillotubular). 
Rarely, micropapillary architecture can be seen. Typically these grow as a 
polypoid mass projecting into the lumen of the stomach. 
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 Mucinous carcinoma: 
 Carcinomas containing large amounts of extracellular mucin in 
more than 50% of the tumour area are called as Mucinous carcinomas. In 
some cases, the cells form glands lined by columnar mucus-secreting cells 
(well differentiated type). In few others, disaggregated ribbons or clusters 
of cells floating in lakes of mucin are seen (poorly differentiated type). 
There may also be mucin in the inter-glandular stroma. Scattered signet-
ring cells, if seen, do not dominate the histological picture. They 
commonly occur as polypoid, fungating or ulcerative growths. 
Signet ring cell carcinoma: 
These are carcinomas composed predominantly of single cells or 
small clusters of cells with intra-cytoplasmic mucus vacuoles which 
accounts for more than 50% of the tumour. These cells have nuclei which 
push against cell membranes forming a classical signet ring cell 
appearance. The cytoplasm contains acid mucin and stain with Alcian 
blue at pH 2.5. They also have cells with no mucin and cells with 
eosinophilic granular cytoplasm having neutral mucin. This tumour which 
is more common in younger patients usually occurs in the distal stomach. 
They usually infiltrate the wall of the stomach diffusely and are 
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accompanied by marked fibrosis giving rise to the linitis plastica 
appearance on macroscopic examination. 
 
The Goseki Classification (1992) 
(62)
:  
According to the degree of tubular differentiation and the amount 
of intracellular mucin present, Goseki et al
(62)
 proposed the following 
classification 
Group I    - has well differentiated tubules & poor intracellular mucin 
Group II   - has well differentiated tubules & plentiful intracellular mucin   
Group III - has poorly differentiated tubules & poor intracellular mucin 
Group IV - has poorly differentiated tubules & plentiful intracellular 
mucin 
Carneiro Classification (1997)
 (63)
: 
 Carneiro et al gave a much simpler system classifying the tumours 
into glandular, isolated cell carcinomas, solid variety and a mixed type 
showing mixture of glandular and isolated cell types. 
The rare variants of gastric carcinoma include 
 
Squamous cell 
carcinoma 
(64)
, Adenosquamous
 
Carcinoma
(65)
,Small cell Carcinoma
(66)
,
 
Parietal cell carcinoma
(67)
, Medullary carcinoma with lymphoid stroma
(68)
,  
Hepatoid adenocarcinoma
(69)
, Choriocarcinoma
(70)
, Gastric carcinoma 
with rhabdoid features 
(71)  
and Carcinosarcoma.
(72)
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Grading Of Gastric Carcinoma: 
 Three tier grading system is used for grading gastric 
adenocarcinoma. 
Well differentiated: shows well-formed glands, often resembling 
metaplastic intestinal epithelium. 
Moderately differentiated:  intermediate between well differentiated and 
poorly differentiated. 
Poorly differentiated: shows highly irregular glands that are recognized 
with difficulty, or shows single cells that remain isolated or arranged in 
clusters with mucin secretions.   
SPREAD OF GASTRIC CARCINOMA: 
 Direct spread after penetration through serosa to pancreas, liver, 
spleen, transverse colon and omentum occurs. Direct spread to lower part 
of esophagus and proximal part of duodenum is also seen. Lymphatic 
spread along the lesser & greater curvature lymphatics to left gastric, 
hepatic and celiac nodes occur. More distant spread to paraaortic and 
mesenteric nodes, through the thoracic ducts to supraclavicular nodes 
may also occur. Incidence of lymph node metastasis seem to increase 
with depth of invasion into the stomach wall.
(73)
 
Haematogenous spread occurs mainly to liver, rarely to lung, 
adrenals, peritoneum and ovaries. Unusual sites such as kidney, spleen, 
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uterus and meninges are more often involved in diffuse type
(74)
. 
Transperitoneal spread is seen as secondary deposits in omentum, 
peritoneum and mesentery. 
STAGING: 
 The TNM staging system
(75)
 is widely used as it is the best 
available predictor of prognosis and the recent TNM staging proposed by 
AJCC is given in Annexure III. 
PROGNOSIS: 
The prognosis of gastric carcinoma varies from country to country. 
The overall survival rate in the Western countries is 4 to 13%
(76)
 which is 
poor compared to Japan which shows the best results with an overall 5-
year survival rate of 89% for early carcinoma and 46% for advanced 
carcinoma. This is atleast partly by the greater frequency of superficial 
carcinomas, and aggressive Japanese surgical approach to treatment with 
extensive and meticulous lymph node dissection
(77)
. Different criteria in 
the differential diagnosis of severe dysplasia and carcinoma between 
Japan and Western countries may also contribute for some of the 
differences
(78)
. 
PROGNOSTIC FACTORS: 
 Any variable that provides useful information in assessing the 
outcome of a disease at the time of diagnosis are called as prognostic 
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factors. They may be clinical factors, morphological factors and/or 
genetic / molecular factors.  
The clinical factors which indicate poor prognosis are young age 
and proximal location of gastric cancers
(76)
. The 5- year survival rates of 
the cardia tumours are under 20%
(79)
 and the median survival is  only 
about 7 months
(80)
.  
 The pathological factors play a more useful role in assessing 
prognosis. A few important ones are the following: 
1. Tumour size: Small size is associated with a better prognosis but this is 
closely linked to depth of penetration
(81)
  
2. Tumour stage: This is the most significant prognostic factor. Depth of 
invasion is considered in staging which is directly proportional to the 
chance of distant metastasis
(82)
. 
3. Microscopic type and grading: Intestinal type tumours in Lauren‘s 
classification has relatively better prognosis than diffuse types
(83)
. 
4. Lymphocytic response: Presence of inflammatory infiltrate at tumour 
and normal tissue interface is associated with good patient survival
(84)
. 
5. Lymphovascular invasion:  Indicates infiltration of tumour cells into 
vascular spaces. It predicts the risk of recurrence and distant metastasis. 
6. Perineural invasion: When present has poor prognosis when compared 
to negative cases
(85)
. 
20
7. Regional lymph node involvement: When nodal involvement is present, 
5-year survival rate drops to below 10% and it is 50% in the node 
negative cases. The number of nodes involved is also significant. Overall 
survival rate decreases as the number of positive node increases
(86)
. 
 Other factors found to have poor prognosis are tumour necrosis, 
infiltrative margins of tumour and involvement of surgical margins. 
 Many molecular biomarkers are identified which play an important 
prognostic role in gastric carcinoma management. DNA aneuploidy has 
been reported in about 40–50% of gastric carcinomas. It has been found 
that aneuploid tumours are significantly associated with both lymph node 
and distant metastases and show lower survival rates compared to diploid 
cancers
(87)
. Over expression of HER-2/Neu which is a transmembrane 
epidermal growth factor receptor protein is reported to have poorer 
outcome
(88)
, but some studies showed no such association
(127)
. Studies 
based on immunohistochemistry showed that p53 protein over expression 
is associated with decreased survival
(90)
 but some studies failed to confirm 
this
(91)
. E-cadherin, a transmembrane protein plays a significant role in 
maintenance of intercellular connections. Germline mutations in E-
cadherin gene are associated with cancers of diffuse type and aggressive 
behaviour
(92)
. Other factors like increased expression of p27kip1
(93)
, 
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cathepsin D
(94)
, loss of  Fhit protein
(95)
  and increased proliferation 
indices
(96)
 are shown to be associated with reduced survival. 
E Cadherin: 
The malignant potential of cancer manifests by the ability of 
tumour cells to spread from primary site and form metastases in distant 
regions. A number of different steps in the complex metastatic process 
show alterations in the adhesive properties of tumour cells 
(97-99)
. One of 
the major molecules mediating adhesion between epithelial cells is the 
calcium-dependent cell adhesion molecule E Cadherin. This 120-
kilodalton transmembrane glycoprotein, is predominantly localized to the 
lateral cell border and is associated with the contractile cytoskeleton, 
mediates homotypic adhesion & plays an important role in organization 
and maintenance of the tissue structure 
(100-102)
. The selective loss of E-
cadherin expression or function is shown to be associated with changes in 
cellular phenotype, with the development of invasive behaviour of tumour 
cells, effects which can be reversed by transfection of E-cadherin-
encoding cDNA
(103,104)
.  
Results of immunohistochemical investigations indicate that E 
Cadherin expression is decreased in various human carcinomas in  
vivo
(105-108)
. The frequency of reduced expression of E Cadherin in various 
studies range from 32 to 92% and conflicting results were found. For 
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example, Shiozaki et al
(109)
  reported a reduced E-cadherin expression in 
undifferentiated tumours, Shimoyama and Hirohashi
(110)
 could find no 
correlation between E-cadherin expression and the differentiation of the 
tumour and, in fact, observed that nearly two-thirds of the 
undifferentiated gastric carcinomas investigated were E-cadherin positive. 
Level of E Cadherin expression can be measured by measuring the level 
of soluble E Cadherin in serum of the patient or by immunohistochemical 
staining of the tissues. The scoring system used for measuring E Cadherin 
expression using immunohistochemistry is given in Annexure V. 
 
 EGFR: 
The epidermal growth factor receptor (EGFR) gene, also called Erb 
B, is located at chromosomal region 7p12. It encodes a 170-kDa 
transmembrane tyrosine kinase receptor, which is a member of the EGFR 
family
(112)
.  EGFR is activated by binding to its ligands (epidermal growth 
factor or transforming growth factor-alpha), which results in 
homodimerization or heterodimerization with another member of EGFR 
family
(113)
. This causes receptor activation and is followed by 
phosphorylation of specific tyrosine residues within the cytoplasmic tail, 
which in turn stimulates the downstream signalling pathway which 
regulates cell proliferation, migration, adhesion, differentiation and 
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survival
(113)
. The frequency of EGFR over expression and ⁄ or 
amplification in Gastric carcinoma has been variously reported as ranging 
from 18 to 44%.
(114-116).
  Recently, the new therapeutic agents targeting 
EGFR has attracted attention. They either bind to extracellular domain of 
the receptor (eg:cetuximab, matuzumab and panitumumab), where they 
compete with the natural ligand binding to the receptor and  block 
activation of that receptor or they compete with adenosine triphosphate 
binding to the tyrosine kinase portion of  endodomain of the receptor and 
they abrogate the receptor‘s catalytic activity (eg: gefitinib, erlotinib and 
lapatinib). Both groups of compounds are effective in blocking the 
downstream receptor-dependant signaling pathway.  For patients with 
gastric cancer, a few clinical trials have been performed with these drugs 
but with ambiguous results. One clinical trial has found that a 
subpopulation of Gastric carcinoma patients showed evidence of gefitinib 
sensitivity. Accurate evaluation of the EGFR protein and ⁄ or EGFR gene 
expression status in patients with Gastric carcinoma is important for 
determining patient‘s eligibility for new targeted therapy. 
Increased expression of this EGFR protein can be studied by either 
Immunohistochemical method or by Fluorescent In Situ Hybridization 
(FISH) method. Immunohistochemically a positive reaction is considered 
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in the presence of brown transmembrane immunostaining and the scoring 
system used to evaluate expression of EGFR is given in Annexure V. 
 
p53:   
The human TP53 gene was cloned in 1985 and its character as a 
tumour suppressor gene was discovered in 1989 by Bert Vogelstein. It is 
considered the ―Guardian of the genome‖ and is located on the 17p 
chromosome, coding for a protein of 53 kD. The role of p53 is central in 
cell - cycle regulation, DNA repair and cell apoptosis. The production of 
p53 is increased in response to cellular insults or DNA damage which 
then induces cell - cycle arrest at the G1/S junction. Thus, p53 is essential 
for control of tumour growth, apoptosis & maintaining genome stability. 
Normal p53 protein is rapidly removed from the nucleus, but mutant form 
has a prolonged half-life, leading on to intranuclear accumulation, thus 
detectable immunohistochemically. Correlation between the over 
expression of p53 and the poor prognosis and survival of patients have 
been observed in several studies but several other studies have failed to 
confirm this
(120.121)
. Overall prevalence of p53 immunoreactivity in 
advanced gastric carcinoma ranges from 35 to 65% as shown by several 
studies. Over expression of p53 protein is more common in intestinal-type 
carcinomas than in diffuse tumours
(119)
. Most commonly used methods for 
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detection of these mutations are immunohistochemistry, flow-cytometry, 
PCR and genomic sequencing. Immunohistochemically positive reaction 
is considered when brown nuclear immunostaining is observed and the 
scoring system used to identify p53 positive cases by 
Immunohistochemistry is given in Annexure V. 
 
HER-2/Neu: 
HER-2/Neu oncogene, also known as c-erbB- 2, encodes a 
transmembrane tyrosine kinase receptor, homologous to epidermal 
growth factor receptor
(123)
. HER molecule belongs to a family of 
glycoproteins which consist of an extracellular domain for binding 
ligands, a lipophilic transmembrane domain, and an intracellular domain 
which carries tyrosine kinase activity. HER-2/Neu gene, located on 
chromosome 17q21, is related to the oncogene v-erbB of the avian 
erythroblastosis virus. Protein encoded by this gene – p185 – is a growth 
factor receptor involved in growth and progression of malignant cells.  
The prognostic value of c-erbB-2 has been mainly shown in breast cancer 
in which patients with over expression of this gene have a significantly 
lower relapse free and overall survival rate compared to patients without 
over expression 
(124,125)
. There are also studies suggesting that over 
expression of this protein is a new, independent prognostic factor for 
26
overall survival in gastric cancer
(126)
. But, some studies have failed to find 
an association with prognosis 
(127,128)
. Also, with the availability of the 
monoclonal antibody trastuzumab, HER-2/Neu can be the target of 
therapy, adding to the importance of research on HER-2/Neu. 
Immunohistochemistry and fluorescence in situ hybridization (FISH) are 
the techniques routinely recommended for determining HER-2/Neu 
status.                  
Immunohistochemically, a positive reaction is considered in the 
presence of brown transmembrane immunostaining and the scoring 
system to identify HER-2/Neu over expression is given in Annexure V. 
Immunohistochemistry: 
 Albert Coons et al in 1941 first labelled antibodies directly with 
fluorescent isocyanate. Nakane and Pierce et al in 1966, introduced 
indirect labelling technique in which unlabelled antibody is followed by 
second antibody or substrate. Various stages of development of 
Immunohistochemistry include peroxidase – antiperoxidase method 
(1970), alkaline phosphatase labelling (1971),  avidin biotin method 
(1977) and two layer dextrin polymer technique (1993) 
(129)
.  
Antigen Retrieval: 
Antigen retrieval can be done by the following different techniques 
to unmask the antigenic determinants of fixed tissue sections. 
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1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval 
3. Pressure cooker antigen retrieval 
4. Microwave and trypsin antigen retrieval 
Proteolytic Enzyme Digestion: 
Huank et al in 1976 introduced this technique to breakdown 
formalin cross linkages and to unmask the antigen determinants. The most 
commonly used enzymes include trypsin and proteinase
(130)
. The 
disadvantages include over digestion, under digestion and antigen 
destruction. 
Microwave Antigen Retrieval: 
This is a new technique most commonly used in current practice. 
Microwave oven heating involves boiling formalin fixed paraffin sections 
in various buffers for rapid and uniform heating 
(129)
. 
Pressure Cooker Antigen Retrieval: 
Miller et al in 1995 compared and proved that pressure cooking 
method has fewer inconsistencies, less time consuming and can be used to 
retrieve large number of slides than in microwave method
(131)
. 
Pitfalls of Heat Pre-treatment: 
Drying of sections at any stage after heat pre-treatment destroys 
antigenicity. Nuclear details are damaged in poorly fixed tissues. Fibers 
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and fatty tissues tend to detach from slides while heating. Not all antigens 
are retrieved by heat pre-treatment and also some antigens like PGP 9.5 
show altered staining pattern. 
Detection Systems: 
After addition of specific antibodies to the antigens, next step is to 
visualize the antigen antibody reaction complex. The methods employed 
are direct and indirect methods. In the direct method, primary antibody is 
directly conjugated with the label. Most commonly used labels are 
flourochrome, horse radish peroxidase and alkaline phosphatase. Indirect 
method is a two-step method in which labelled secondary antibody reacts 
with primary antibody bound to specific antigen. The use of peroxidase 
enzyme complex or avidin biotin complex further increases the sensitivity 
of immunohistochemical stains
(129)
. In 1993, Pluzek et al introduced 
enhanced polymer one step staining, in which large numbers of primary 
antibody and peroxidase enzymes are attached to dextran polymer back 
bone. This is the rapid and sensitive method
(132)
. Dextran polymer 
conjugate two step visualization system is based on dextran technology in 
Epos system. This method has greater sensitivity and is less time 
consuming. 
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 MATERIALS AND METHODS 
This study is a prospective study of gastric carcinoma conducted in 
the Institute of Pathology, Madras Medical College and Rajiv Gandhi 
Government General Hospital, Chennai during the period of January 2011 
to December 2011. A total of 10,357 cases were received in our Surgical 
Pathology department during January 2011 to December 2011. Of these, 
677 were gastric specimens including 578 endoscopic biopsies and 99 
gastrectomy specimens. Of the 677 gastric specimens, 321 were non 
neoplastic, 4 were benign and 352 were malignant cases. Of the 352 
malignant cases (including 254 endoscopic biopsies and 98 gastrectomy 
specimens) 338 were adenocarcinoma, 8 were lymphoma, 5 were GIST, 1 
was neuroendocrine tumour.  
 Source of Data 
  Endoscopic biopsy from stomach as well as resected specimens 
(subtotal, total, radical and palliative gastrectomy) from the Department 
of Surgery, Surgical Gastroenterology, Surgical Oncology and Geriatric 
surgery, Government General Hospital which were received in Institute of 
Pathology, Madras Medical College during the period of January to 
December 2011 and reported as adenocarcinoma were included for the 
study. A total 667 gastric specimens were received during January to 
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December 2011, out of which 338 cases were reported as 
adenocarcinoma. 
Inclusion criteria 
All gastric adenocarcinoma cases reported in both endoscopic 
biopsies as well as resected specimens, irrespective of age and sex were 
included for the study. 
Exclusion criteria 
 - Non neoplastic lesions and benign tumours of stomach. 
 - Malignancies other than adenocarcinoma. 
 - Tumours located in gastroesophageal junction. 
 - Gastrectomies performed for reasons other than gastric tumours. 
Method of data collection 
 Detailed history of the cases regarding age, sex, clinical 
presentation, investigations done along with the findings, type of 
procedure done were obtained for all the gastric specimens received 
during the period of study. Haematoxylin and Eosin stained 4 micron 
thick sections of the paraffin tissue blocks of the cases were prepared and 
cases reported as gastric adenocarcinoma were selected. Among the 338 
adenocarcinoma cases reported, 50 patients (25 endoscopic biopsies and 
25 resected specimens) attending the medical oncology OP for follow up 
were selected for Immunohistochemical analysis. 
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 Variables studied 
   The following clinical and pathological parameters were evaluated. 
Age, gender, size, location (Eso-cardia, body, pyroloantrum, pangastric), 
gross appearance (ulcerative, nodular, ulceroproliferative, diffuse), 
histological types (diffuse, signet ring cell, tubular, papillary, mucinous), 
Lauren's classification (intestinal, diffuse, indeterminate), depth of 
infiltration (T1 -invasion of mucosa and submucosa,T2- invasion of 
muscularis mucosa,T3- invasion of subserosa, T4-invasion of serosa or 
adjacent organs), grade (well differentiated, moderately differentiated, 
poorly differentiated). The resected specimens were evaluated for 
presence of lymphatic invasion, vascular invasion, perineural invasion, 
and lymphocytic response. 25 endoscopic biopsies (unresectable cases 
with locally advanced stage or distant spread) and 25 resected specimens 
of patients attending the medical oncology department for follow up and 
further treatment were selected and their representative formalin fixed 
paraffin embedded tissue samples were subjected to 
immunohistochemical analysis with a panel of 4 markers i.e., E Cadherin, 
EGFR, p53 and  HER-2/Neu. 
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 Immunohistochemical evaluation 
Antigen Vendor Species(clone) Dilution Positive control 
E Cadherin Biogenex Mouse Ready to use Stomach 
EGFR Biogenex Mouse Ready to use Stomach 
p53 Biogenex Mouse Ready to use Stomach 
HER-2/Neu Biogenex Mouse Ready to use Stomach 
 
  Immunohistochemical analysis was done in paraffin embedded 
tissue samples using supersensitive polymer HRP system based on non-
biotin polymeric technology. 4 micron thick sections from formalin fixed 
paraffin embedded tissue samples were transferred onto gelatin coated 
slides. Heat induced antigen retrieval was done. The antigen was bound 
with mouse monoclonal antibody (Biogenex) against E Cadherin, EGFR, 
p53 and HER-2/Neu proteins and then detected by the addition of 
secondary antibody conjugated with horse radish peroxidase polymer and 
diaminobenzidine substrate. Step by step procedure of 
Immunohistochemistry is given in Annexure IV. 
Interpretation and scoring 
The immunohistochemically stained slides were analyzed for the 
presence of reaction, cellular localization, percentage of cells stained and 
intensity of staining. Cytoplasmic membrane staining was assessed for       
E Cadherin, EGFR, and HER-2/Neu and nuclear staining was assessed for 
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p53. Details of the scoring pattern applied to classify positive/ negative 
cases for HER-2/Neu, p53, EGFR and reduced expression/ normal 
expression in case of E Cadherin is given in Annexure V. 
Patients follow up 
  Mean follow-up time was 11.5 months, with a range of 2 months to 
20 months. To eliminate bias due to deaths directly resulting from 
complications of operation  patients who died within 6 weeks of surgery 
were excluded from the statistical analysis of survival. 
Data entry 
 All the data collected and the results obtained were entered into 
Excel 2007. 
Statistical analysis 
The statistical analysis was performed using statistical package 
STATA 11(Statacorp). For continuous variables like age and size of 
tumour, Student T test was done to obtain the results. For discrete 
variables like gender, gross appearance, histological type, Lauren's 
classification, grade, depth of infiltration, lymphovascular invasion, 
perineural invasion and survival, Pearson chi square test and Fisher's 
exact test were used to obtain results. Reports were expressed in 
percentage or odds ratio with 95% as CI. P value of 0.05 was taken as cut 
off point to determine statistically significant results. 
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OBSERVATION AND RESULTS 
During January to December 2011 a total of 10,357 cases were 
received for histopathological examination in the Institute of Pathology, 
Madras Medical College. Among the 667 gastric specimens, 352 were 
malignant cases. Among the malignant cases, 338 were adenocarcinoma, 
8 were lymphoma, 5 were GIST and 1 was neuroendocrine tumour. 
Adenocarcinoma of stomach constituted for 52.77% of all the gastric 
specimens received and 3.26% of all total cases received during 2011. 
Gastric carcinoma had a peak incidence in the age group of 55 to 
64 years. The oldest age of presentation was 84 years and youngest age of 
presentation was 21 years. Among the 338 cases 244 (72.19%) were 
males and 94 cases (27.81%) were females. Gastric cancer in this study 
showed increased incidence among 55 to 64 years and overall male 
preponderance (Table 1 and Chart1) 
Table 1: Age and Sex Distribution of study participants 
Age Males (%) Females (%) Total (%) 
0 to  40 years 24 (7.1) 25 (7.4) 49 (14.50) 
41 to 54 years 71 (21) 31 (9.2) 102 (30.18) 
55 to 64 years 92 (27) 20 (6) 112 (33.14) 
65 and above  57 (16.9) 18 (5.4) 75 (22.18) 
Total 244 (72) 94 (28) 338 (100) 
          
35
   The mean age of incidence of gastric carcinoma was higher in 
males (56.49 years) than that of females (50.87 years) and this difference 
in age incidence was found to be statistically significant. (Table2) 
 
Table2: Mean age of Incidence in males and females 
Sex No of Cases Mean of 
age(yrs) 
Std deviation Mann Whitney 
test 
Male 244 56.49 .708 P Value 
0.003 Female 94 50.87 1.415 
 
     
 Of the 338 cases, increased occurrence (61.83%) was noted in the 
pyloroantral region. (Figure 3 & Chart 2) 
 
 
 
      
36
  
 Ulceroproliferative type (58.88%) was the most common gross 
appearance, followed by ulcerative type (26.63%), nodular type (10.36%) 
and diffuse type (4.13%). (Figure 4 & Chart 3) 
 
 
 
Figure 4: Distribution of various gross types of gastric cancer 
      
             
 Among the various histological subtypes, tubular type of gastric 
carcinoma was the most common. (Table 3 & Chart 4) 
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Table 3: Distribution of Gastric Cancer based on Histological 
Subtype 
Histological subtype No of cases (%) 
Tubular 189 (55.91) 
Diffuse 71 (21.01) 
Signet ring cell 44 (13.02) 
Mucinous 19 (5.62) 
Papillary 15 (4.44) 
Total 338 (100) 
     
 
 On applying Lauren's classification, of the 338 cases, 205 were 
intestinal type, 127 were diffuse type and 8 were indeterminate. (Table 4 
& Chart 5) 
 
Table 4: Distribution of Gastric Cancer based on Lauren's 
Classification 
Lauren's type No of cases (%) 
Intestinal 205 (60.6) 
Diffuse 127 (37.5) 
Indeterminate 6 (1.9) 
Total 338 (100) 
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 Depending on the histological grading, distribution of the gastric 
cancers were as shown in Table 5 & Chart 6 
 
Table 5: Distribution of Gastric Cancer based on Histological 
Grading 
Histological grade No of cases (%) 
Well differentiated 62 (18.34) 
Moderately differentiated 113 (33.43) 
Poorly differentiated 163 (48.23) 
Total 338 (100) 
    
 
 
Depth of infiltration was studied in the 93 resected specimens (total 
and subtotal gastrectomies). 3 cases showed invasion up to submucosa 
(T1), 17 cases showed invasion into muscular layer (T2), 55 cases showed 
invasion into subserosa (T3), 19 cases showed invasion into serosa or 
adjacent structures (T4).(Figure 5 & Chart 7) 
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 Figure 5: Distribution according to Depth of Infiltration 
 
 
 Size of the tumour was studied in the 93 resected specimens, and 
the distribution was as shown in Figure 6 & Chart 8. 
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 Figure 6: Distribution of Gastric Cancer according to size 
 
 Of the 93 resected specimens 80.65% cases showed lymphatic 
infiltration, 59.54% cases showed vascular invasion. Perineural invasion 
was seen only in 34.41% of cases. Lymphocytic response was seen in 
39.48% cases. (Table 6 & Chart 9) 
Table 6: Distribution of Other Prognostic Factors in Gastric 
Carcinoma 
Prognostic 
factor 
Present (%) Absent (%) Total (%) 
Lymphatic 
invasion 
75 (80.65) 18 (19.35) 93 (100) 
Vascular 
invasion 
55 (59.14) 38 (40.86) 93 (100) 
Perineural 
invasion 
32 (34.41) 61 (65.59) 93 (100) 
Lymphocytic 
response 
37 (39.78) 56 (60.22) 93 (100) 
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Results of Immunohistochemical analysis: 
 Of the 338 cases, a total of 50 cases comprising 25 resected 
specimens and 25 endoscopic biopsies were selected and subjected to a 
panel of 4 immunohistochemical markers, i.e., E Cadherin, EGFR, p53 
and HER-2/Neu. 
 Among the 50 cases, 29 (58%) cases showed reduced expression 
for E Cadherin, 13 (26%) cases showed EGFR over expression, 27 (54%) 
cases showed positivity for p53, and 10 (20%) cases showed HER-2/Neu 
over expression. (Table 7 & Chart 10) 
 
Table 7: Percentage of Expressions of E Cadherin, EGFR, p53 and 
Her2/ Neu in Gastric Cancer: 
IHC  
Para- 
Meter 
 
   E Cadherin (%) 
 
   EGFR (%) 
 
      p53 (%) 
 
HER-2/Neu (%) 
Result 
(%) 
Reduced  
expression 
Normal  
expression 
Positive Negative Positive Negative Positive Negative 
29 (58) 21 (42) 13(26) 37 (74) 27(54) 23 (46) 10(20) 40 (80) 
Total         50 (100)                  50 (100)                  50 (100)                  50 (100)         
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Correlation of E Cadherin with Various Clinicopathological Factors: 
The mean age of patients with normal E Cadherin expression was 
54.57 years and that of patients with reduced E Cadherin expression was 
53.89 years. There was no significant difference in the age at presentation 
between the two groups (Table 8 & Chart 11) 
 
Table 8: Association of age of patient with E Cadherin expression 
E Cadherin No of 
cases 
Mean age in 
years  
Std 
deviation 
Mann 
Whitney test 
Reduced  
expression 
29 53.89  10.65  
P Value 
0.837 Normal 
expression 
21 54.57  12.47 
 
      
 Of the cases showing reduced E Cadherin expression, 17 were 
males and 12 were females and there was no significant difference in sex 
wise distribution of gastric cancer showing reduced E Cadherin 
expression. (Table 9 & Chart 12) 
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Table 9: Association of Gender with E Cadherin Expression 
Sex Male (%) Female (%) Total (%) 
Reduced expression 17 (58.62) 12 (41.38) 29 (100) 
Normal expression 12 (57.14) 9 (42.86) 21 (100) 
Total No. of Cases 29 (58) 21 (42) 50 (100) 
Pearson chi 
 square test 
                       
                           P value  0.917 
 
 In the present study, among the 29 cases showing reduced E 
Cadherin expression, increased frequency (65.54%) of cases were from 
pyloroantral region but the association was not statistically significant. 
(Table 10 & Chart 13) 
Table 10: Association of Site with E Cadherin Expression  
 
Site 
 
Eso-
Cardia 
(%) 
 
Body 
(%) 
 
Pyloro 
antrum(%) 
 
Pan-
gastric(%) 
 
Total 
(%) 
 
Fisher’s 
Exact test 
Reduced 
expression 
 
6 (20.68) 
 
1(3.44) 
 
19 (65.54) 
 
3 (10.34) 
 
29(100) 
 
P Value 
 
0.751 
Normal 
expression 
 
3(14.28) 
 
0 
 
16 (76.2) 
 
2 (9.52) 
 
21(100) 
Total No. 
of Cases 
 
9(18) 
 
1(2) 
 
35 (70) 
 
5 (10) 
 
50(100) 
 
       On correlating with gross appearance, among the 29 cases showing 
reduced E Cadherin expression, 19 cases (65.5%) were ulceroproliferative 
type but this association was not statistically significant. (Table11 & 
Chart 14) 
44
Table 11: Association of Gross Appearance of Tumour with                  
E Cadherin Expression 
Gross type Ulcerative 
(%) 
Nodular 
(%) 
Ulcero- 
Proliferative 
(%) 
Diffuse 
(%) 
Total 
(%) 
Fisher’s 
exact 
test 
Reduced 
expression 
5 (17.24) 2 (6.89) 19 (65.51) 3 (10.36) 29(100)    
 
P value 
0.858 
Normal 
expression 
3 (14.28) 3 (14.28) 13 (61.90) 2 (9.54) 21(100) 
Total No. 
of Cases 
 
8 (16) 
 
5 (10) 
 
32 (64) 
 
5 (10) 
 
50(100) 
 
         
       Among the 25 resected specimens for which expression of E 
Cadherin was studied, 6 cases were showing reduced E Cadherin 
expression, among which 4 cases (66.66%) were less than 5 cm. There 
was no significant association between size of the tumour and E Cadherin 
expression. (Table 12 & Chart 15)  
Table 12: Correlation of Tumour Size with E Cadherin Expression 
 
Size 
 
<5cm (%) 
 
>=5cm (%) 
 
Total (%) 
Fisher’s 
exact test 
Reduced 
expression 
 
4(66.67) 
 
2(33.33) 
 
 6(100) 
 
P Value 
0.428 
Normal 
expression 
 
15(78.95) 
 
4(21.05) 
 
19(100) 
Total No. of 
Cases 
 
19(76) 
 
6(24) 
 
25(100) 
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 On correlating with the histological types, higher number (55.2%) 
of cases with reduced E Cadherin expression was seen in tubular type. 
There was no significant association between histological type and E 
Cadherin expression. (Table 13 & Chart 16) 
 
Table 13:  Association of Histological Type with E Cadherin 
Expression 
Histological 
type 
Diffuse 
type 
(%) 
Signet 
ring cell 
type 
(%) 
Tubular 
type 
(%) 
Papillary  
type (%) 
Mucinous 
type (%) 
Total 
(%) 
Fisher
s exact 
test 
Reduced 
expression 
 
7 (24.2) 
 
4 (13.8) 
 
16(55.2) 
 
0 
 
2 (6.8) 
 
29  (58) 
  
 
P 
Value 
0.314 
Normal 
expression 
 
2 (9.5) 
 
1 (4.8) 
 
16(76.1) 
 
1  (4.8) 
 
1 (4.8) 
 
21  (42) 
Total No. 
of Cases 
 
9  (18) 
 
5 (10) 
 
32 (64) 
 
1  (2) 
 
3  (6) 
 
50(100) 
 
 
    On comparing and analysis using Lauren's classification, greater 
frequency of reduced expression was noted with intestinal type (55.2%) 
than diffuse type (44.8%) but the association was not statistically 
significant. (Table14 & Chart 17) 
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Table 14:  Association of Lauren's Classification with E Cadherin 
Expression 
 Lauren’s Intestinal 
type (%) 
Diffuse type 
(%) 
Total 
(%) 
Fisher’s 
exact test 
Normal 
expression 
 
17  (80.9) 
 
4   (19.1) 
 
21  (100) 
  
P value  
0.058 
 
Reduced 
expression 
 
16  (55.2) 
 
13  (44.8) 
 
29  (100) 
Total No. of 
Cases 
 
33  (66) 
 
17  (34) 
 
50  (100) 
   
Reduced expression of E Cadherin was seen to be more with 
increasing tumour grade. Among the cases showing reduced E Cadherin 
expression, 13.8% were well differentiated, 27.5% were moderately 
differentiated and 58.7% were poorly differentiated grades. (Table 15 & 
Chart 18) 
 
Table 15: Association of Tumour Grade with E Cadherin Expression 
 Grade Well  
Differentiated 
(%) 
Moderately  
Differentiated 
(%) 
Poorly  
Differentiated 
(%) 
Total 
(%) 
Fisher’s 
exact test 
Reduced 
expression 
 
4 (13.8) 
 
8  (27.5) 
 
17 (58.7) 
 
29(100) 
  
 
P Value  
0.208 
Normal 
expression 
 
5 (23.8) 
 
9  (42.8) 
 
7   (33.4) 
 
21(100) 
Total No. 
of Cases 
 
9 (18) 
 
17 (34) 
 
24  (48) 
 
50(100) 
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On correlating with the depth of infiltration for the 25 resected 
specimens for which E Cadherin expression was studied, among the cases 
showing reduced E Cadherin expression, increased frequency (66.67%) of 
cases showed infiltration up to T3 level but the association was not 
statistically significant. (Table16 & Chart 19) 
 
 
Table 16: Association of Depth of Infiltration with E Cadherin 
Expression 
 
Depth 
 
T2 (%) 
 
T3 (%) 
 
T4 (%) 
 
Total (%) 
Fisher’s 
exact test 
Reduced  
Expression 
 
1  (11.11) 
 
6  (66.67) 
 
2  (22.22) 
 
9   (100) 
 
  
P value 
 0.489 
Normal  
Expression 
 
2  (12.50) 
 
13 (81.25) 
 
1  (6.25) 
 
16  (100) 
Total No. 
of Cases 
 
3  (12) 
 
19  (76) 
 
3  (12) 
 
25  (100) 
   
Among the 25 resected specimens for which E Cadherin expression 
was studied, 9 cases showed reduced expression. Of these 9 cases, 92.9% 
of cases had lymphatic invasion, 77.8% cases had vascular invasion, 
66.7% cases had perineural invasion and only 11.1% cases had 
lymphocytic response but these associations were not statistically 
significant. (Table 17 & Charts 20 to 23). 
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Table 17: Association of other Prognostic Markers with E Cadherin 
Expression 
Patient  
Character
-istic 
Lymphatic 
 Invasion (%) 
Vascular  
Invasion (%) 
Perineural 
 Invasion (%) 
Lymphocytic  
Response (%) 
Absent Present Absent Present Absent Present Absent Present 
Reduced 
Expression 
 
1 (7.1) 
 
13(92.9) 
 
2(22.2) 
 
7 (77.8) 
 
3(33.3) 
 
6 (66.7) 
 
8 (88.9) 
 
1 (11.1) 
Normal  
Expression 
 
3(27.3) 
 
8 (72.7) 
 
6(37.5) 
 
10(62.5) 
 
8 (50) 
 
8 (50) 
 
8 (50) 
 
8 (50) 
Fisher‘s 
exact test 
 
 P Value 0.073 
 
 P Value 0.366 
 
 P Value 0.444 
 
 P Value 0.141 
      
 
 Among the 50 cases followed up for a mean period of 11.5 
months, 79.3% with reduced expression were dead and only 20.7% with 
reduced expression were alive and the association was found to be 
statistically significant. (Table 18 & Chart 24) 
Table 18: Association of Survival of patient with E Cadherin 
Expression 
Survival of 
patient 
Alive (%) Dead (%) Total 
(%) 
Pearson  
chi square 
test  
Reduced 
expression 
6 (20.7) 23 (79.3) 29 (100)  
P Value 
0.004 
Normal  
expression 
12 (57.1) 9 (42.9) 21 (100) 
Total No. of 
Cases 
18 (36) 32 (64) 50 (100) 
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Correlation of EGFR with Various Clinicopathological Factors: 
The mean age of patients showing EGFR over expression was 
55.76 years and that of patients without EGFR over expression was 53.62 
years. No significant association was found between age of presentation 
and EGFR over expression. (Table 19 & Chart 11) 
Table 19: Association of age of patient with EGFR Expression 
EGFR No of 
cases 
Mean of age 
in years 
Std deviation Mann 
Whitney test  
Negative 37 53.62 11.6 P Value 
0.562 Positive 13 55.76 10.9 
 
 Among the cases showing EGFR over expression, 64.3% were 
males and 35.7% were females and there was no significant difference in 
sex wise distribution of gastric cancer showing EGFR over expression. 
(Table 20 & Chart 12) 
Table 20: Correlation of Gender with EGFR Expression 
Sex Male (%) Female (%) Total (%) 
Negative 20  (54.1) 17  (45.9) 37   (100) 
Positive 9    (64.3) 4    (35.7) 13   (100) 
Total No of Cases 29  (58) 21  (42) 50   (100) 
Fisher‘s Exact test                             P Value 0.340 
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  Among the cases showing EGFR over expression, increased 
frequencies of cases (92.4%) were from pyloroantral region and the 
distribution was not statistically significant. (Table 21 & Chart 13) 
 
Table 21: Association of Site of tumour with EGFR Expression 
 
Site 
 
Eso 
Cardia (%) 
 
Body 
(%) 
 
Pyloroantrum 
(%) 
 
Pangastric 
(%) 
 
Total 
(%) 
Pearson 
chi 
square 
test 
Negative 8(21.6) 1(2.7) 23(62.7) 5(13) 37 (100) P Value 
0.285 Positive 1(7.6) 0 12(92.4) 0 13 (100) 
Total No 
of Cases 
9(18) 1(2) 35(70) 5(10) 50(100) 
 
 Among the cases with EGFR over expression, 69.2% were 
ulceroproliferative type, 15.4% were nodular type, 15.4% were ulcerative 
type, and none of the cases were of diffuse type. Association of EGFR 
over expression with gross appearance was not found to be statistically 
significant. (Table 22 & Chart 14) 
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Table 22: Association of Gross Appearance of Tumour with EGFR 
Expression 
Gross  
Type 
Ulcerative 
(%) 
Nodular 
(%) 
Ulcero 
Prolifer 
-ative(%) 
Diffuse 
(%) 
Total 
(%) 
Fisher’s 
exact test 
Negative 6 (16.2) 3 (8.1) 23 (62.2) 5 (13.5) 37 (100)  
P Value  
0.858 
Positive 2 (15.4) 2 (15.4) 9 (69.2) 0 13 (100) 
Total No of 
Cases 
8 (16) 5 (10) 32 (64) 5 (10) 50(100) 
 
Of the 25 resected specimens for which EGFR expression was 
studied, 8 cases showed over expression, among which 75 % were less 
than 5 cm in size but the association was not statistically significant. 
(Table 23 & Chart 15) 
Table 23: Association of Tumour Size with EGFR Expression 
Size <5cm (%) >=5cm (%) Total (%) Fisher’s 
exact test 
Negative 13  (76.5) 4  (23.5) 17  (100)  
P Value 
0.668 
Positive  6   (75) 2  (25)  8   (100) 
Total No 
of Cases 
19  (76) 6  (24) 25  (100) 
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On correlating with histological type, among the cases showing 
EGFR over expression, higher number of cases (76.2%) showed tubular 
type and the distribution was not statistically significant. (Table 24 & 
Chart 16) 
Table 24:  Association of Histological Type with EGFR Expression 
Histologi-
cal type 
Diffuse 
type (%) 
Signet 
ring cell 
type (%) 
Tubular 
type 
(%) 
Papillary 
type 
(%) 
Mucinous 
type 
(%) 
Total 
(%) 
Fisher’s 
exact test 
Negative 7  (24.1) 4  (13.8) 16 (55.2) 0 2  (6.9) 29(100)  
P Value 
0.154 
Positive 2  (9.4) 1  (4.8) 16 (76.2) 1  (4.8) 1  (4.8) 21(100) 
Total No 
of Cases 
9  (18) 5  (10) 32  (64) 1  (2) 3  (6) 50(100) 
 
 
 Among the 13 cases showing EGFR over expression, 76.9% were 
intestinal type and only 23.1% were of diffuse type and the association 
was not statistically significant. (Table25 & Chart 17) 
 
Table 25: Association of Lauren's Classification with EGFR 
Expression 
 Lauren’s Intestinal 
type (%) 
Diffuse type 
(%) 
Total 
(%) 
Fisher’s 
exact test 
Negative 23  (62.7) 14  (37.3) 37  (100)  
P value 
0.334 
Positive 10  (76.9)  3   (23.1) 13  (100) 
Total No of 
Cases 
33  (66) 17  (34) 50  (100) 
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 Among the cases showing EGFR over expression, higher number 
of cases showed moderately differentiated grade (61.5%) and the 
association was found to be statistically significant (Table 26 & Chart 18) 
 
Table 26: Association of Tumour Grade with EGFR Expression 
  
Grade 
Well  
Differentiated 
(%) 
Moderately  
Differentiated 
(%) 
Poorly  
Differentiated 
(%) 
Total 
(%) 
Fisher’s 
exact 
test 
Negative 7  (18.9) 9  (24.4) 21  (56.7) 37(100)  
P value  
0.044 
Positive 2  (15.4) 8  (61.5) 3    (23.1) 13(100) 
Total No of 
Cases 
9 (18) 17 (34) 24 (48) 50(100) 
    
On correlating with the depth of infiltration for the 25 resected 
specimens for which EGFR expression was studied, 66.66% of cases with 
EGFR over expression were showing infiltration up to T3 level, 22.23% 
were showing infiltration up to T4 level and only 11.1% were showing 
infiltration up to T1 level. No statistically significant association between 
depth of infiltration and EGFR expression was found. (Table 27 & Chart 
19). 
 
 
 
54
Table 27: Association of Depth of Infiltration with EGFR Expression 
Depth T2 (%) T3 (%) T4 (%) Total (%) Fisher’s 
exact test 
Negative 2  (12.5) 13 (81.3) 1  (6.2) 16 (100)  
P value 
0.498 
Positive 1  (11.11)  6  (66.67) 2  (22.22) 9   (100) 
Total No 
of Cases 
3  (12) 19  (76) 3  (12) 25 (100) 
   
 
 77.8% of cases with EGFR over expression showed lymphatic 
invasion, 44.4% of case with EGFR over expression showed vascular 
invasion, 55.6% of cases with EGFR over expression showed perineural 
invasion and 44.4% of cases with EGFR over expression showed 
lymphocytic response. None of these associations were statistically 
significant. (Table 28 & Charts 20 to 23) 
 
Table 28: Association of Other Prognostic Markers with EGFR 
Expression 
 Patient  
Characte
-ristics 
Lymphatic 
 Invasion (%) 
Vascular  
Invasion (%) 
Perineural 
 Invasion (%) 
Lymphocytic  
Response (%) 
Absent Present Absent Present Absent Present Absent Present 
Negative 2(12.5) 14(87.5) 3(18.7) 13(81.3) 7(43.7) 9(56.3) 11(68.7) 5(31.3) 
Positive 2(22.2) 7(77.8) 5(55.6) 4(44.4) 4(44.4) 5(55.6) 5(55.6) 4(44.4) 
Fisher‘s 
exact test 
P Value 
0.340 
P Value 
0.096 
P Value 
0.988 
P Value 
0.602 
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  Among the 50 cases followed up for a mean period of 11.5 
months, 53.8% of cases with EGFR over expression were alive. The 
association between EGFR over expression and survival was not 
statistically significant. (Table 29 & Chart 24) 
 
Table 29: Association of survival with EGFR expression 
Survival of 
patient 
Alive (%) Dead (%) Total (%) Pearson  
chi square 
test  
Negative 25 (67.6) 12 (32.4) 37 (100)  
P Value 
0.156 
Positive 7 (53.8) 6 (46.2) 13 (100) 
Total No of 
Cases 
32 (64) 18 (36) 50 (100) 
 
Correlation of P53 with Various Clinicopathological Factors: 
 The mean age of patients with positivity for p53 was 52.3 years 
and that of patients with negativity of p53 was 55.7 years. There was no 
significant difference in the age of presentation among cases in the two 
groups. (Table 30 & Chart 11) 
 
Table 30: Association of Age of patient with p53 Expression 
  P53 No of cases Mean of 
age(yrs) 
Std deviation Mann Whitney 
test 
Negative 23 55.7 9.58  P Value 
0.388 Positive 27 52.3 12.67 
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Among the cases showing p53 over expression, 51.8% were males 
and 48.2% were females and the association was not found to be 
statistically significant. (Table 31 & Chart 12) 
Table 31:  Association of Gender with P53 Expression 
Sex Male (%) Female (%) Total (%) 
Negative 15 (65.2) 8 (34.8) 23 (100) 
Positive 14 (51.8) 13 (48.2) 27 (100) 
Total No. of Cases 29 (58) 21 (42) 50 (100) 
Pearson chi square test                      P Value 0.340 
          
 On correlating with site, higher number (66.7%) of cases with p53 
over expression was from pyloroantral region. The association of site of 
tumour with p53 expression was not found to be statistically significant.   
(Table 32 & Chart 13) 
Table 32: Association of Site of tumour with p53 Expression 
 
Site 
Eso-
Cardia 
(%) 
Body 
(%) 
Pyloro- 
antrum 
(%) 
Pangastric 
(%) 
Total 
(%) 
Fisher’s 
exact 
test 
Negative 3 (13.1) 1(4.3) 17 (73.9) 2 (8.7) 23(100)  
P Value 
0.691 
Positive 6 (22.2) 0 18 (66.7) 3 (11.1) 27(100) 
Total No. of 
Cases 
9 (18) 1(2) 35 (70) 5 (10) 50(100) 
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On correlating with gross type, among the 27 cases showing p53 
over expression, 66.7% were ulceroproliferative type, 18.5% were 
ulcerative type, 11.1% were diffuse type and only 3.7% were of nodular 
type. Association of gross type with p53 expression was not statistically 
significant. (Table33 & Chart 14) 
 
 
Table 33: Association of Gross Appearance of Tumour and p53 
Expression 
Gross 
type 
Ulcera- 
tive 
(%) 
Nodular 
(%) 
Ulcero-
prolif 
-erative 
(%) 
Diffuse 
(%) 
Total 
(%) 
Fisher’
s exact 
test 
Negative 3 (13.1) 4 (17.3) 14 (60.9) 2 (8.7) 23(100)  
P Value 
0.441 
Positive 5 (18.5) 1 (3.7) 18 (66.7) 3(11.1) 27(100) 
Total 
No. of 
Cases 
8 (16) 5 (10) 32 (64) 5 (10) 50(100) 
 
 On correlating the size of tumour with p53 expression, of the 12 
cases showing over expression of p53, 75% were less than 5 cm but this 
association was not statistically significant. (Table 34 & Chart 15) 
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Table 34: Association of Tumour Size with p53 Expression 
Size <5cm (%) >=5cm (%) Total (%) Fisher’s 
exact test 
Negative 10  (76.9) 3  (23.1) 13  (100)  
P Value 
0.678 
Positive  9  (75) 3  (25) 12  (100) 
Total No. of 
Cases 
19  (75) 6  (25) 25  (100) 
 
 
 Among the cases showing p53 over expression, 74.1% were of 
tubular type, 3.7% were of papillary type. Diffuse type, signet ring cell 
type and mucinous type constituted for 7.4% of cases each. No 
statistically significant association between histological type and p53 
expression was found. (Table 35 & Chart 16) 
 
Table 35: Association of Histological Type with p53 Expression 
Histologi-
cal type 
Diffuse 
type 
(%) 
Signet 
ring cell 
type 
(%) 
Tubular 
type 
(%) 
Papillary 
type 
(%) 
Mucinous 
type 
(%) 
Total 
(%) 
Fisher’s 
exact 
test 
Negative 7 (30.4) 3 (13.1) 12 (52.1) 0 1 (4.4) 23(100)  
PValue 
0.197 
Positive 2 (7.4) 2 (7.4) 20 (74.1) 1 (3.7) 2 (7.4) 27(100) 
Total No. 
of Cases 
9 (18) 5 (10) 32 (64) 1 (2) 3 (6) 50(100) 
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On correlating with Lauren's classification, 77.8% of cases with 
p53 positivity were of intestinal type and only 22.2% of cases with p53 
positivity were of diffuse type and the association was not found to be 
statistically (Table 36 & Chart 17) 
 
Table 36: Association of Lauren's Classification with p53 Expression 
 Lauren’s Intestinal 
type (%) 
Diffuse type 
(%) 
Total 
(%) 
Pearson chi 
square test 
Negative 12 (52.2) 11 (47.8) 23 (100)   
P value  
0.057  
Positive 21 (77.8)  6 (22.2) 27 (100) 
Total No. of Cases 33 (66) 17 (34) 50 (100) 
   
     Positivity for p53 was comparatively more with moderately 
differentiated and poorly differentiated grades (37.1% each) than well 
differentiated grade (25.8%). (Table 37& Chart 18) 
Table 37: Association of Tumour Grade with p53 Expression  
  
Grade 
Well  
Differentiated 
(%) 
Moderately  
Differentiated 
(%) 
Poorly  
Differentiated 
(%) 
 
Total 
(%) 
Fisher’s 
exact 
 Test 
 Negative 2  (8.8)  7  (30.4) 14  (60.8) 23(100)  
P value  
0.159 
Positive 7  (25.8) 10 (37.1) 10  (37.1) 27(100) 
Total No. 
of Cases 
9  (18) 17 (34) 24  (48) 50(100) 
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  On correlating with the depth of infiltration for the 25 resected 
specimens for which p53 expression was studied, 84.6% of cases with 
p53 positivity showed infiltration up to T3 level and 15.4 % cases showed 
infiltration up to T2 level none of the cases were showing T4 level of 
infiltration. Association of depth of infiltration with p 53 expression was 
not statistically significant.(Table 38 & Chart 19). 
 
Table 38: Association of Depth of Infiltration with p53 Expression 
Depth T2 (%) T3 (%) T4 (%) Total(%) Fisher’s exact test 
Negative 1 (8.3) 8 (66.7) 3 (25) 12 (100)  
P value 
 0.152 
Positive 2 (15.4) 11 (84.6) 0 13 (100) 
Total No. 
of Cases 
3 (12) 19 (76) 3 (12) 25 (100) 
 
 Of the 25 resected specimens for which p53 expression was 
studied, 84.7% cases with p53 positivity showed lymphatic invasion, 
61.6% of cases with p53 positivity showed vascular invasion, 53.8% of 
cases with p53 positivity showed perineural invasion and 30.8% cases 
with p53 positivity showed lymphocytic response. These associations 
were not statistically significant. (Table 39 & Charts 20 to 23) 
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Table 39: Association of Prognostic Markers with p53 Expression 
 Patient  
Characte
-ristics 
Lymphatic 
 Invasion (%) 
Vascular  
Invasion (%) 
Perineural 
 Invasion (%) 
Lymphocytic  
Infiltration (%) 
Absent Present Absent Present Absent Present Absent Present 
Negative 2(16.7) 10(83.3) 3(25) 9(75) 5(41.7) 7(58.3) 7(58.3) 5(41.7) 
Positive 2(15.3) 11(84.7) 5(38.4) 8(61.6) 6(46.2) 7(53.8) 9(69.2) 4(30.8) 
Fisher‘s 
exact test 
P Value 
 0.930 
P Value  
0.471 
P Value  
0.821 
P Value 
 0.571 
     
        On correlating with survival, no statistically significant association 
was found between p53 expression and survival of patient. (Table 40 & 
Chart 24) 
Table 40: Association of survival with p53 expression 
Survival of 
patient 
Alive  
(%) 
Dead 
 (%) 
Total 
 (%) 
Pearson  
chi square test  
Negative 16 (69.6) 7 (30.4) 23 (100)  
P value 
0.449 
Positive 16 (59.3) 11 (40.7) 27 (100) 
Total No of 
Cases 
32 (64) 18 (36) 50 (100) 
 
 
Correlation of HER-2/Neu with Various Clinicopathological Factors: 
 The mean age of patients with HER-2/Neu over expression was 
49.6 years and that of patients without HER-2/Neu over expression was 
55.32 years. There was no significant difference in the age at presentation 
between the two groups (Table 41 & Chart 11) 
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Table 41: Association of Age of patient with HER-2/Neu Expression 
  HER-2/Neu No of cases Mean of  
age  (yrs) 
Std 
deviation 
Mann 
Whitney test 
Negative 40 55.32 11.24 P value 
0.155 Positive 10 49.6 11.07 
 
 
Of the cases showing HER-2/Neu over expression, 40% were 
males and 60% were females and there was no significant difference in 
sex wise distribution. (Table 42 & Chart 12) 
Table 42:  Association of Gender with HER-2/Neu Expression 
Sex Male (%) Female (%) Total (%) 
Negative 25 (62.5) 15 (37.5) 40 (100) 
Positive 4 (40) 6 (60) 10 (100) 
Total No. of Cases 29 (58) 21 (42) 50 (100) 
Fisher‘s exact test                               P Value 0.197 
 
    Among the cases showing HER-2/Neu over expression, 60% 
were from pyloroantral region, 20% were from eso-cardiac region. Only 
10% of cases from body and 10% of cases with pangastric involvement 
showed HER-2/Neu over expression. Association of site of tumour with 
HER-2/Neu over expression was not statistically significant. (Table43 & 
Chart 13) 
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 Table 43: Association of Site with HER-2/Neu Expression 
Site Eso- 
Cardia 
(%) 
Body 
(%) 
Pyloro- 
antrum 
(%) 
Pangastric 
(%) 
Total 
(%) 
Fisher’s 
exact 
test 
Negative 7(17.5) 0 29 (72.5) 4 (10) 40 (100)  
P Value 
0.334 
Positive 2(20) 1(10) 6 (60) 1 (10) 10 (100) 
Total No. of 
Cases 
9(18) 1(2) 35 (70) 5 (10) 50 (100) 
 
       Among the cases showing HER-2/Neu over expression, 70% were 
ulceroproliferative type, 20% were ulcerative type, only 10% were diffuse 
type and none were nodular type. No statistically significant association 
was found between gross appearance and HER-2/Neu over expression. 
(Table44 & Chart 14) 
 
Table 44: Association of Gross Appearance with HER-2/Neu 
Expression 
Gross type Ulcerative 
(%) 
Nodular 
(%) 
Ulcero 
Proliferative 
(%) 
Diffuse 
(%) 
Total 
(%) 
Fisher’s 
exact 
test 
Negative 6 (15) 5 (12.5) 25 (62.5) 4 (10) 40 (100)  
P Value 
0.695 
Positive 2 (20) 0 7 (70) 1 (10) 10 (20) 
Total No. of 
Cases 
8 (16) 5 (10) 32 (64) 5 (10) 50(100) 
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 Among the cases showing HER-2/Neu over expression, 75% were 
less than 5 cm and the association was not statistically significant. (Table 
45 & Chart 15) 
Table 45: Association of Tumour Size with HER-2/Neu Expression 
Size <5cm (%) >=5cm (%) Total (%) Fisher’s 
exact test 
Negative 13(76.5) 4(23.5) 17(100)  
P Value 
0.668 
Positive 6(75) 2(25) 8(100) 
Total No. of 
Cases 
19(76) 6(24) 25(100) 
 
 Of the cases showing HER-2/Neu over expression, 80% were 
tubular type, 10% were papillary type, 10% were mucinous type and none 
were diffuse or signet ring cell types. No statistically significant 
association was found between histological type and HER-2/Neu over 
expression. (Table 46 & Chart 16) 
Table 46: Association of Histological Type with HER-2/Neu 
Expression 
Histologi-
cal type 
Diffuse 
type 
(%) 
Signet 
ring cell 
type 
(%) 
Tubular 
type 
(%) 
Papillary 
type 
(%) 
Mucinous 
type 
(%) 
Total 
(%) 
Fisher’
s exact  
test 
Negative 9 (22.5) 5 (12.5) 24 (60) 0 2 (5) 40(100)  
PValue 
0.084 
Positive 0 0  8  (80) 1 (10) 1 (10) 10(100) 
Total No. 
of Cases 
9 (18) 5 (10) 32 (64) 1 (2) 3 (6) 50(100) 
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  On correlating with Lauren's classification, 90% of cases with 
HER-2/Neu over expression were of intestinal type and only 10% of cases 
with HER-2/Neu over expression were diffuse type but the association 
was not statistically significant. (Table 47 & Chart 17) 
Table 47: Association of Lauren's Classification with HER-2/Neu 
Expression 
 Lauren’s Intestinal 
type (%) 
Diffuse  
type (%) 
Total 
(%) 
Pearson chi 
square test  
Negative 24 (60) 16 (40) 40 (100)  
P value 
0.073 
Positive 9 (90) 1 (10) 10 (100) 
Total No. of Cases 33 (66) 17 (34) 50 (100) 
   
             Positivity for HER-2/Neu was seem to be more with poorly  
differentiated cases (40%) than moderately differentiated (30%) or well 
differentiated (30%) cases, but the association was not statistically 
significant. (Table 48 & Chart 18) 
Table 48: Association of Tumour Grade with HER-2/Neu Expression 
 Grade Well  
Differentiated 
(%) 
Moderately  
Differentiated 
(%) 
Poorly  
Differentiated 
(%) 
 
Total 
(%) 
Fisher’s 
exact 
test 
Negative 6 (15) 14 (35) 20 (50) 40(100) P value  
0.542 
Positive 3 (30) 3 (30) 4 (40) 10(100) 
Total No. 
of Cases 
9 (18) 17 (34) 24 (48) 50(100) 
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  Among the 25 resected specimens for which HER-2/Neu 
expression was studied, all the cases with HER-2/Neu over expression 
showed depth of infiltration up to T3 level but the association was not 
statistically significant. (Table 49 & Chart 19) 
 
Table 49: Association of Depth of Infiltration with HER-2/Neu 
Expression 
 
Depth 
 
T2 (%) 
 
T3 (%) 
 
T4 (%) 
 
Total (%) 
Fisher’s 
exact test 
Negative 3 (15.8) 13 (68.4) 3 (15.8) 19 (100)  
P value 
 0.287 
Positive 0 6  (100) 0 6  (100) 
Total No. 
of Cases 
3  (12) 19 (76) 3 (12) 25 (100) 
 
             100% of cases with HER-2/Neu over expression showed 
lymphatic invasion, 66.7% of cases with HER-2/Neu over expression 
showed vascular invasion and perineural invasion, only 16.7% of cases 
with HER-2/Neu over expression showed lymphocytic response. Of 
these, only the association of lymphocytic response to HER-2/Neu over 
expression was statistically significant. (Table 50 & Charts 20 to 23) 
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Table 50: Association of Prognostic Markers with HER-2/Neu 
Expression 
 Patient  
Characte
-ristics 
Lymphatic 
 Invasion (%) 
Vascular  
Invasion (%) 
Perineural 
 Invasion (%) 
Lymphocytic  
Response (%) 
Absent Present Absent Present Absent Present Absent Present 
Negative 4 (21.5) 15(78.5) 6(31.6) 13(68.4) 9(47.4) 10(52.6) 11(57.9) 8(42.1) 
Positive 0 6(100) 2(33.3) 4(66.7) 2(33.3) 4(66.7) 5(83.3) 1(16.7) 
Fisher‘s 
exact test 
P Value 
0.444 
P Value 
0.425 
P Value 
0.763 
P Value 
0.003 
      
        
   Among the 50 cases followed up for a mean period of 11.5 months, 
no statistically significant association was found between HER-2/Neu 
expression and survival. (Table 51 & Chart 24) 
 
Table 51: Association of survival with HER-2/Neu 
Survival of 
patient 
Alive  (%) Dead (%) Total (%) Fisher’s 
exact test 
Negative 24 (60) 16 (40) 40 (100) P Value 
0.201 Positive 8 (80) 2 (20) 10 (100) 
Total No. of 
Cases 
32 (64) 18 (36) 50 (100) 
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  On comparing the expression of E Cadherin, EGFR, p53 and 
HER-2/Neu with each other, reduced expression of E Cadherin was found 
to be significantly associated with EGFR over expression and HER-2/Neu 
over expression. (Table 52) 
Table 52: Comparison of expressions of E Cadherin with EGFR, p53 
and Her2/Neu: 
 E Cadherin EGFR p53 HER-2/ Neu 
E Cadherin K=1 K=0.2201** 
 
K=0.2101 K=0.4248** 
 
EGFR K=0.2201** 
 
K= 1 K= -0.0786 K= 0.1573 
 
p53 K=0.2101 
 
K= -0.0786 
 
K= 1 K= 0.1221 
 
Her2/ Neu K=0.4248** 
 
K= 0.1573 
 
K= 0.1221 
 
K= 1 
 
  K- Kappa value, **-obtained significant P Value 
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Figure 7: Gastric Carcinoma- Ulcerative 
 
Figure 8: Gastric Carcinoma- Proliferative 
1355/11
1 
4701/11 
  
Figure 9: Gastric Carcinoma- Ulceroproliferative 
 
 
Figure 10: Gastric Carcinoma- Linitis Plastica 
373/11
1 
2972/11 
  
Figure 11: Gastric Carcinoma- Mucinous Type 
 
 
Figure 12: Gastric Carcinoma- Papillary type 
 
196/11
1 
604/11 
  
 
Gastric adenocarcinoma- Different grades 
 
           
Figure 13: Well differentiated 
grade showing well formed 
glands lined by malignant cells, 
40x, HPE- 74/11 
Figure14: Moderately differentiated 
grade showing cells arranged in 
groups and glands, 40x, HPE-
2048/11
 
 
Figure15: Poorly differentiated grade                                                                                    
with cells arranged in sheets, 40x, HPE-3914/11 
   
 
  
Lauren’s Classification 
        
Figure 16: Intestinal type. Tumour 
cell arranged in glandular pattern, 
40x, HPE- 2048/11     
Figure17: Diffuse type. Single cells &     
small clusters of cells infiltrating      
muscular layer, 10x, HPE- 2259/11                
 
 
WHO Classification-Tubular Carcinoma 
    
Figure 18:  Irregular dilated & 
branching tubules of varying sizes, 
10x, HPE- 5019/11 
Figure 19: Tubules lined by columnar 
cells showing atypia and mitosis, 40x, 
HPE- 5019/11
 
 
 
 WHO Classification- Papillary carcinoma 
    
Figure 20: Cross sections of 
papillae with central 
fibrovascular core, 40x, HPE-
604/11 
Figure 21: Thin papillae with central 
fibrovascular core lined by        
malignant cells, 40x, HPE- 604/11
 
 
WHO Classification- Mucinous carcinoma 
    
Figure 22:  Clusters of cells 
floating in extracellular mucin, 
10x, HPE- 196/11 
Figure 23:  Singly dispersed cells 
floating    in abundant extracellular 
mucin, 10x, HPE-372/11
 
 
 
  
WHO Classification- Signet ring cell carcinoma 
     
Figure 24: Sheets of diffusely 
infiltrating signet ring cells, 10x, 
HPE- 373/11 
Figure 25: Signet ring cells with    
intracellular mucin and peripherally 
pushed nuclei, 40x, HPE- 373/11
 
 
WHO Classification- Diffuse carcinoma 
    
Figure 26:  Diffusely infiltrating 
malignant cells, 10x, HPE-4850/11 
 
Figure 27: Small clusters and single 
cells diffusely infiltrating muscular 
layer, 10x, HPE-2259/11
 
 
 Other Prognostic Factors 
 
      
Figure 28: Lymphatic invasion 
40x, HPE- 352/11             
Figure 29: Vascular Invasion, 
40x, HPE- 5016/11
 
 
 
    
 Figure 30: Perineural 
Invasion, 40x, HPE- 6411/11                
Figure 31: Lymphocytic 
Response, 40x, HPE- 2836/11                                  
 
 
 
  Immunohistochemical Analysis of E Cadherin in Gastric Carcinoma 
 
    
Figure 32: E Cadherin Score 
0.Negative staining in tumour cells 
(Adjacent foci with normal glands 
show intense membranous 
positivity),10x, HPE-5631/11 
Figure 33:E Cadherin Score 1+, 
Incomplete membranous 
staining in less than  20% cells, 
40x, HPE- 8896/11
 
     
Figure 34: E Cadherin Score 2+, 
moderate intense complete 
membranous staining in 60% of 
tumour cells, 40x, HPE- 8270/11 
Figure 35: E Cadherin Score 3+, 
strong intense complete 
membranous staining in all 
tumour cells, 40x, HPE- 1306/11
 
 
 Immunohistochemical Analysis of EGFR in Gastric Carcinoma 
 
     
Figure 36: EGFR Score 0, No 
staining in tumour cells, 40x,      
HPE- 1658/11 
 
Figure 37: EGFR Score 1+, 
Incomplete membranous 
staining in 40% of tumour  
cells, 40x, HPE- 628/11
 
    
Figure 38: EGFR Score 2+, 
moderately intense complete 
membranous staining in all tumour 
cells, 40x, HPE- 5384/11 
Figure 39: EGFR Score 3+, 
Complete strong intense 
membranous staining in all 
tumour cells, 40x, HPE- 
7965/11
 
 
  Immunohistochemical Analysis of p53 in Gastric Carcinoma 
 
    
Figure 40: p53 Negative, No 
staining in all tumour cells, 10x, 
HPE- 763/11 
 
Figure 41: p53 Negative, very 
weak nuclear staining in < 5% of 
tumour cells, 40x, HPE- 1382/11
 
    
Figure 42: p53 Positive, Strong 
intense nuclear staining in > 90% 
tumour cells, 10x, HPE- 1279/11 
 
Figure 43: p53 Positive, Strong 
intense nuclear staining in > 
95% of tumour cells, 40x, HPE- 
1355/11
 
 
 
 Immunohistochemical Analysis of HER-2/Neu in Gastric Carcinoma 
 
      
Figure 44: HER-2/Neu Score 0, No 
staining in all tumour cells, 40x,       
HPE- 1126/11 
 
Figure 45: HER-2/Neu Score 1+, 
Incomplete membranous staining in 
40% of tumour cells, 40x,               
HPE- 3073/11
 
      
Figure 46: HER-2/Neu Score 2+, 
Moderate intense complete staining 
in 90% of tumour cells, 10x, HPE- 
576/11 
 
 
 
Figure 47: HER-2/Neu Score 3+, 
Strong intense complete 
membranous staining in all 
tumour cells, 40x, HPE- 763/11
  
 
 
 FIGURE 48: IMMUNOHISTOCHEMISTRY EQUIPMENT AND KIT 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
  
  
  
  
 
  
 
  
 
 
  
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
DISCUSSION 
           Gastric cancer is the fourth most common cancer worldwide 
(1).
 It is 
a disease with a high death rate (~700,000 per year) making it the second 
most common cause of cancer death worldwide after lung cancer 
(2)
. More 
than 50% of cases present in advanced stages which are unresectable 
making cure impossible. The overall 5 year survival rate is 28% 
irrespective of the stage at which the patient presents. 
            Many biological markers are being studied in several parts of the 
world to identify their possible role in the evaluation of gastric carcinoma 
and thus in clinical outcome. Among them, immunohistochemical staining 
for cell adhesion molecule E Cadherin, cell cycle regulator p53 and 
growth factor receptors HER-2/Neu and EGFR have been proposed to 
have prognostic value. 
  In this study, immunohistochemical evaluation was done in 50 
gastric carcinoma cases; attempt was made to correlate the expression of 
E Cadherin, EGFR, p53 and HER-2/Neu with various clinicopathological 
factors and known prognostic factors of gastric carcinoma. 
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 In the Institute of Pathology, Madras Medical College, 338 cases 
of gastric adenocarcinoma were reported during the year 2011. The age of 
the patients ranged from 21 years to 84 years, with a mean age of 52.5 
years. The mean age of incidence in males was higher than that of 
females (56.49 years & 50.87 years respectively) and the difference was 
statistically significant. The age group showing the greatest incidence of 
gastric carcinoma was 55 to 64 years. This is in concurrence with the 
study done by Zhang HK et al 
(133)
, who observed a mean age of 52.2 
years with the range between 25 and 75 years.  
In the current study, the incidence of gastric carcinoma in males 
and females were 72% and 28% respectively. This is in concurrence with 
the study by Nobuyuki Igarashi et al
(134)
 who observed an incidence of 
74.1% and 25.9% in males and females respectively. 
  The most common site of gastric carcinoma in this study was 
pyloroantral region (61.83%), which is similar to the study by Czyewski J 
et al
(135)
, showing occurrence of 60% of cases in the pyloroantral region. 
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 Table 53: Comparison of Location of Gastric Carcinoma: 
Tumour 
Location 
H R Raziee 
et al
(10) 
C Fondevila 
et al
(122) 
Czyzwski J 
et al
(135) 
Current 
Study 
Esocardia 37% 7% 15.6% 13.91% 
Body 33% 40% 20% 19.82% 
Pyloroantrum 30% 51% 60% 61.83% 
Pangastric - 2% 4.4% 4.44% 
 
Among the various histological types, tubular carcinoma was the 
most common type accounting for 55.92 % of cases in this study, which is 
almost similar to that observed by Daniela et al
(136)
 in their study. 
 
Table 54: Comparison of Histological Type of Gastric cancer: 
Histological  
type 
Kakeji et al
(137) Daniela et al
(136) 
Current 
study 
Diffuse - 4.9% 21.01% 
Signet ring cell 3.1% 27.8% 13.02% 
Tubular 89.5% 45.9% 55.91% 
Papillary 2.2% 8.3% 4.44% 
Mucinous 5.2% 13.1% 5.62% 
     
  On using Lauren's classification, the most common histological 
subtype in this study was intestinal type (60.6%).This is in concurrence 
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with the findings observed by Fondevila et al
(122)
 and Gabbert et al
(119)
 
showing 62% and 63.3% respectively. 
 
Table 55: Comparison According to Lauren’s Classification: 
Lauren’s 
type 
H R Raziee 
 et al
(10) 
Fondevila 
 et al
(122)
 
Gabbert  
et al
(119) 
Current 
study 
 
Intestinal 
 
74% 
 
62% 
 
63.4% 
 
60.6% 
 
Diffuse 
 
21% 
 
38% 
 
28.5% 
 
37.5% 
 
Indeterminate 
 
5% 
 
- 
 
8.1% 
 
1.9% 
 
  In this study poorly differentiated grade tumours were more 
common than other grades accounting for 48.22% of cases, which is 
similar to observations made by Daniela et al
(136)
 (64%) and Fondevila et 
al
(122)
 (49%) in their studies. 
 
Table 56: Comparison of Histological Grades of Gastric Carcinoma: 
 
Grade 
H R Raziee 
 et al
(10) 
Daniela  
et al
(136) 
Fondevila 
 et al
(122) 
Current 
study 
Well 
differentiated 
 
54% 
 
3.2% 
 
4% 
 
18.34% 
Moderately 
differentiated 
 
17% 
 
32.8% 
 
47% 
 
33.43% 
Poorly 
differentiated 
 
29% 
 
64% 
 
49% 
 
48.23% 
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In this study, a higher proportion of tumours belonged to T3 
subtype (59.13%) which is similar to the observation made by Giovanni 
et al
(139)
 (66%) in their study. 
 
Table 57: Comparison of Depth of Infiltration: 
Depth of 
Invasion 
Joo Y E et 
al
(138) 
Daniela et 
al
(136) 
Giovanni et 
al
(139) 
Current 
study 
T1 13.4% 6.5% - 3.23% 
T2 24.3% 15.9% 25% 18.28% 
T3 51.2% 27.8% 66% 59.13% 
T4 11.1% 49.8% 9% 19.36% 
 
  Among the resected specimens, 80.65% had lymphatic invasion 
and vascular invasion was seen in 59.54% of cases. This is similar to the 
observations obtained by Ji Yoon Choi et al
(140)
, showing lymphatic 
invasion in 79.35% of cases. 
 In this study, 34.45% cases showed perineural infiltration and 
39.48 % cases showed lymphocytic response, this was similar to the 
results obtained by Luo Tianhang et al
(141)
, showing 31.7% of cases with 
perineural invasion. 
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 Table 58: Comparison of E Cadherin, EGFR, p53 & HER-2/Neu with 
World Statistics: 
 E Cadherin 
Reduced 
Expression  
% 
EGFR 
Positivity 
% 
P53 
Positivity 
% 
HER-
2/Neu 
Positivity 
% 
Current study 58 26 54 20 
Gabbert et al(119)
 
43 - - - 
Barbara Mayer et al(153)
 
92 - - - 
Yoshihidi Shino et al(8)
 
32.2 - - - 
HongKai Zhang et al(133)
 
44 - - - 
Yong Ning Zhou et al(154)
 
46 - - - 
Karatzas G et al(157)
 
67 - - - 
Eva Lieto et al(149)
 
- 44 - - 
M F Filipe et al(150)
 
- 18 - - 
Kim M A et al(7)
 
- 27.4 - - 
Zhiyoung Liam et al(117)
 
- 42 - - 
GennaroGalizia et al(151)
 
- 44 - - 
Hong Suk Song et al(152)
 
- 25.4 - - 
Stefano Cascinu et al(89)
 
- - 50 - 
T Sakaguchi et al(142)
 
- - 50.9 - 
Kamran G et al(143)
 
- - 75 - 
Y E Joo et al(138)
 
- - 34.4 - 
N Igarashi et al(134)
 
- - 58 - 
N E Tzanakis et al(144)
 
- - 65 - 
H R Raziee et al(10)
 
- - - 26 
Cathy B M et al(145)
 
- - - 23 
C Ballestin et al(146)
 
- - - 13.5 
S D Xie et al(147)
 
- - - 18.8 
R Vergara et al(148) - - - 5.6 
Xiu Li Zhang et al(118)
 
- - - 18.6 
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 Reduced expression of E Cadherin was seen in 58% cases, over 
expression of EGFR and HER-2/Neu was seen in 26% & 20% cases 
respectively and positivity for p53 was seen in 54% cases. Comparison of 
expression of the above mentioned markers with other literature is shown 
in Table 58. Various studies showed reduced expression of E Cadherin 
ranging from 32% to 92%, over expression of EGFR ranging from 18% to 
44% , and that of HER-2/Neu ranging from 5% to 23%, and positivity for 
p53 ranging from 35% to 65%. These fluctuations could be due to 
different methodologies used for evaluation and to varying characteristics 
of the studied cases. 
 
Association of E Cadherin with various clinicopathological and 
prognostic factors: 
 Helmut E Gabbert et al
(119)
 (1996) studied 413 cases of gastric 
carcinoma in Germany and found significant association between E 
Cadherin expression and Lauren's classification, histological type and 
grade and no association between depth of infiltration, lymphatic invasion 
and vascular invasion. 
Hong-Kai Zang et al
(133)
 (2004) studied 74 cases in China and 
found significant association of E Cadherin expression with grade of 
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tumour but not with age, sex, location of tumour, size and histological 
type of tumour. 
Yong-Ning Zhou et al
(154)
 (2002) studied 100 cases of gastric 
carcinoma in China and found significant association between E Cadherin 
expression and gross appearance, histological grade but not with tumour 
size and Lauren's classification. 
 Yoo Y E et al
(155)
 (2006) studied 114 cases of gastric carcinoma in 
Korea and found significant association of E Cadherin expression with 
Lauren's classification, but not with size of tumour and depth of 
infiltration. 
Hui-Chun A Chen et al
(156)
 (2003) studied 84 cases in Taiwan and 
found significant association between E Cadherin expression and tumour 
grade, Lauren's classification and depth of infiltration and no association 
with survival. 
 In the present study, there was a direct significant association 
between  E Cadherin expression and survival, reduced E Cadherin 
expression had poor survival. Reduced expression of E Cadherin was 
increased in elderly age group and slight male preponderance was noted.  
Reduced expression of E Cadherin was seen to be increasing with 
increasing grade, but statistically significant association could not be 
ascertained. 
77
 In comparison with the above studies, this study also showed no 
significant association between E Cadherin expression and gross 
appearance, tumour size, histological type, depth of infiltration, lymphatic 
invasion, vascular invasion and perineural invasion. 
 
Correlation of EGFR Expression with Various Clinicopathological 
and Prognostic Factors: 
 Hong Suk Song et al
(152)
 (2004) studied 739 cases of gastric 
carcinoma in Korea and found significant association between EGFR 
expression and high grade of tumour, perineural invasion and no 
association with size of tumour, Lauren‘s type, depth of infiltration. 
Eva Lieto et al
(149)
 (2007) studied 88 cases in Italy and found 
significant association between EGFR expression and increased depth of 
infiltration, increasing grade and poor survival and no association 
between EGFR expression and other clinicopathological factors 
 Gennara Galizia et al
(151)
 (2007) studied 82 cases in Greece and 
found a significant association between EGFR expression with gross 
appearance of tumour, depth of infiltration, lymphovascular invasion and 
poor survival and no association with size of tumour, depth of infiltration, 
grade of tumour and survival of patients. 
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 M.A. Kim et al
(7)
 (2008) studied 511 cases in Korea and observed 
significant association between EGFR over expression and older age of 
patient, increasing tumour grade, increased depth of invasion, and poor 
survival, but no association with other parameters like lymphatic 
invasion, vascular invasion, gross appearance and tumour size. 
Zhiyoung Liam et al
(117)
 (2008) studied 100 cases of gastric 
carcinoma and found no significant association between EGFR 
expression and clinicopathological and prognostic factors or with survival 
of the patients. 
 In the present study, direct significant association was found 
between grade of tumour and EGFR expression, moderately differentiated 
cases showed significant increase in over expression of EGFR. Increased 
frequency of EGFR over expressed cases was seen with male sex, tubular 
histological type and T3 level of infiltration, but statistically significant 
association could not be ascertained. No association was found between 
EGFR expression and tumour location, gross appearance, size, lymphatic 
invasion, vascular invasion, perineural invasion and survival. 
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Correlation of p53 expression with Various Clinicopathological and 
Prognostic Factors. 
 Maehara Y et al
(158)
 (1999) studied 96 cases of gastric carcinoma in 
Japan, and observed statistically significant association between p53 
expression and tumour size, site, lymphatic invasion, vascular invasion, 
depth of infiltration. 
Karman G et al
(143)
 (2004) studied 52 cases of gastric carcinoma in 
Iran, they were able to demonstrate significant association of p53 
expression with histological type, depth of infiltration and tumour grade 
but no association between other factors like lymphatic invasion and 
vascular invasion. 
 Y. E. Joo et al
(138)
 (2006) studied 119 cases in Korea and was able 
to demonstrate significant association between p53 expression and depth 
of infiltration, but not with tumour grade, histological type and survival. 
N. E. Tzanakis et al
(144)
 (2009) studied 93 cases in Greece and they 
were able to demonstrate statistically significant association of p53 
expression with tumour size, location of  tumour, depth of infiltration and 
survival but not with histological type and grade. 
Daniela Lazar et al
(138)
 (2010) studied 61 cases in Romania and 
demonstrated statistically significant association of p53 with tumour 
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grade, Lauren's histological type, depth of infiltration and increased 
survival. 
In the present study, positivity for p53 showed male preponderance, 
increased frequency of Lauren‘s intestinal type, moderately and poorly 
differentiated tumour grades, T3 level of infiltration, but statistically 
significant association could not be ascertained. No association of p53 
positivity was found with site of tumour, gross appearance, size, 
lymphovascular invasion and survival. 
 
Correlation of HER-2/Neu Expression with Various 
Clinicopathological and Prognostic Factors 
 H R Raziee et al
(10)
 (2007) studied 100 cases of gastric carcinoma 
in Iran and found a significant association of HER-2/Neu over expression 
with Lauren's intestinal type of tumour and well differentiated grade, and 
no association between age, gender, location of tumour and depth of 
infiltration. 
Zhiyong Liam et al
(117)
 (2008) studied 100 cases in China and they 
found no significant association of over expression of HER-2/Neu with 
any clinicopathological factors or with survival. 
 S. D. Xie et al
(147)
 (2009) studied 218 cases and they were able to 
demonstrate a statistically significant association of HER-2/Neu over 
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expression with survival of the patient and were not able to demonstrate 
association with any other known clinicopathological and prognostic 
factors. 
P. Vergara et al
(148)
 (2009) studied 90 cases of gastric carcinoma 
and found a statistically significant association of HER-2/Neu over 
expression with depth of infiltration and no association with grade, 
histological subtype or survival. 
 Xie Li Zhang et al
(118)
 (2009) studied 102 cases of gastric cancer in 
Korea and found a significant association between HER-2/Neu over 
expression and Lauren‘s type and depth of infiltration and no association 
with grade, histological type or survival. 
 In this study, a statistically significant association was obtained 
between absence of lymphocytic response and HER-2/Neu over 
expression. HER-2/Neu over expression showed female preponderance. 
Increased frequency of HER-2/Neu over expressed cases were belonging 
to Lauren's intestinal type, poorly differentiated grade, and T3 level of 
infiltration, but statistically significant association could not be 
ascertained. No association was found between HER-2/Neu over 
expression and gross appearance, histological subtype, lymphovascular 
invasion, perineural invasion and survival. 
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 SUMMARY 
 Among the total number of 10,357 cases received in Institute of 
Pathology, Madras Medical College, during 2011; 667 cases were 
gastric specimens,  of which 338 were gastric carcinoma cases; 
accounting for 3.26% of cases. 
 Among the 667 gastric specimens, 321 were non neoplastic, 4 were 
benign and 352 were malignant cases. 
 Gastric carcinoma had a peak incidence in the 55 to 64 years age 
group. The oldest age of presentation was 84 years and the 
youngest age of presentation was 21 years. 
 Mean age of incidence was higher in males (56.49 years) than 
females (50.87 years). 
 Among the 338 carcinoma cases 93 were resected specimens and 
245 were endoscopic biopsies. 
 There was a male preponderance; 72% of the cases were males. 
 The most common site of occurrence was pyloroantral region 
(61.83%). 
 Ulceroproliferative type was the most common morphological type 
accounting for 58.88% of cases. 
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 The most common histological type was tubular carcinoma 
accounting for 55.91% of gastric carcinoma cases. 
 According to Lauren‘s classification the most common subtype was 
intestinal type accounting for 60.6% of cases. 
 Poorly differentiated histological grade was the most common 
grade constituting for 48.23% of gastric carcinoma cases. 
 Most cases presented with T3 level of invasion, accounting for 
59.13% of cases. 
 Most cases (73.1%) were less than 5 cm in size. 
 Lymphatic invasion was noted in 80.65% of cases. 
 Vascular invasion was seen in 59.14% of cases. 
 34.41% of cases showed perineural invasion. 
 Lymphocytic response was seen in 39.78% of cases. 
 Reduced expression of E Cadherin was seen in 29% of cases. 
 Over expression of EGFR was seen in 26% of cases. 
 54% of cases were positive for p53. 
 HER-2/Neu over expression was seen in 20% of cases. 
 E Cadherin showed statistically significant association with 
survival of the patient, reduced expression was associated with 
reduced survival. 
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 Increase in number of cases with reduced E Cadherin expression 
was seen with Lauren‘s intestinal type, poorly differentiated grade, 
presence of lymphatic invasion and absence of lymphocytic 
response. 
 No association was found between E Cadherin expression and age, 
sex, site, gross type, size, histological type, depth of infiltration, 
vascular invasion and perineural invasion. 
 A statistically significant association was found between EGFR 
expression and moderately differentiated grade of tumour. 
 Increase in the number of cases with EGFR over expression was 
seen with tubular type of carcinoma, Lauren‘s intestinal type and 
absence of vascular invasion. 
 No association was found between EGFR expression and age, sex, 
site, gross type, size, depth of infiltration, lymphatic invasion, 
perineural invasion, lymphocytic response and survival. 
 Increase in frequency of cases with p53 positivity was seen with 
tubular type, Lauren‘s intestinal type, moderately and poorly 
differentiated grades and T3 level of infiltration. 
 No association was found between p53 expression and age, sex, 
site, gross type, size, lymphovascular invasion, perineural invasion, 
lymphocytic response and survival. 
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 A significant association was found between HER-2/Neu over 
expression and absence of lymphocytic response in the adjacent 
foci of tumour. 
 Increase in number of cases with HER-2/Neu over expression was 
found to be associated with female sex, Lauren‘s intestinal type and 
T3 level of infiltration. 
 No association was found between HER-2/Neu expression and age, 
site, gross type, size, histological type, grade, lymphovascular 
invasion, perineural invasion and survival. 
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CONCLUSION 
       The incidence of gastric carcinoma in the year 2011 in RGGGH was 
3.26%. Many patients were older than 55 years of age with male 
preponderance which is similar to several other studies conducted 
throughout the world. Females showed a younger mean age of incidence 
compared to males. 29% of cases showed reduced expression of E 
Cadherin. A significant association was found between reduced 
expression of E Cadherin and reduced survival. A significant association 
of EGFR over expression was found with moderately differentiated grade. 
No significant association was found between EGFR expression and 
survival. An increased frequency of cases with p53 positivity showed 
intestinal type of Lauren‘s classification, moderately and poorly 
differentiated grades and no association between p53 positivity and 
survival was found. All the cases which showed HER-2/Neu over 
expression showed T3 level of infiltration, no association with HER-
2/Neu expression and survival was found.  
 To conclude, identifying the expression of E Cadherin, EGFR, P53 
and HER-2/Neu in gastric carcinoma can help to identify patients with 
reduced survival and to identify eligible candidates for targeted therapy. 
A larger sample size and follow up for a longer period might shed more 
light on the role of the above markers in gastric carcinoma. 
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ANNEXURE – I 
PROFORMA 
Case number :        Name : 
HPE number :        Age : 
IP number :         Sex : 
Clinical history : 
Risk factors, if any : 
Clinical diagnosis : 
Imaging : 
Endoscopy : 
Previous HPE report: 
Nature of specimen : Total gastrectomy/Subtotal gastrectomy/Endoscopic 
biopsy 
GROSS: 
Proximal circumference :    Greater curvature: 
Distal circumference :     Lesser curvature : 
Tumour site : 
Tumour size : 
Tumour configuration :     Depth of invasion: 
Margins :   Proximal :   Distal : 
Associated findings : 
 
 MICROSCOPY: 
Histological type : 
Histological grade :  G1 / G2 / G4 / G4 
Lauren‘s classification: 
Depth of invasion : 
Margins :    Proximal : Free / Involved 
Distal : Free / Involved 
Lymphatic invasion : Present / Absent 
Venous invasion : Present / Absent 
Perineural invasion : Present / Absent 
Lymphocytic response : Present / Absent 
Associated findings: 
IMMUNOHISTOCHEMISTRY 
E Cadherin: Intensity &Percentage of cells showing staining- 
EGFR: Intensity &Percentage of cells showing staining- 
P53 score : Intensity &Percentage of cells showing staining- 
HER-2/Neu: Intensity &Percentage of cells showing staining- 
 
 
 
 
 
ANNEXURE - II 
WHO CLASSIFICATION OF GASTRIC TUMOURS 
 
 
 
EPITHELIAL TUMOURS 
Intraepithelial neoplasia – 
Adenoma 
Carcinoma 
Adenocarcinoma 
Intestinal type 
Diffuse type 
Papillary adenocarcinoma 
Tubular adenocarcinoma 
Mucinous adenocarcinoma 
Signet-ring cell carcinoma 
Adenosquamous carcinoma 
Squamous cell carcinoma 
Small cell carcinoma 
Undifferentiated carcinoma 
Others 
Carcinoid (well differentiated 
endocrine neoplasm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NON-EPITHELIAL 
TUMOURS 
Leiomyoma 
Schwannoma 
Granular cell tumour 
Glomus tumour 
Leiomyosarcoma 
GI stromal tumour 
   -Benign 
   -Uncertain malignant potential 
   -Malignant 
Kaposi sarcoma 
Others 
 
Malignant lymphomas 
   -Marginal zone B-cell     
lymphoma of MALT-type 
   -Mantle cell lymphoma 
   -Diffuse large B-cell lymphoma 
   -Others 
SECONDARY TUMOURS 
  
ANNEXURE III 
TNM STAGING OF GASTRIC TUMOURS 
T – Primary Tumour 
TX - Primary tumour cannot be assessed 
T0 - No evidence of primary tumour 
Tis - Carcinoma in situ 
T1 - Tumour invades lamina propria or submucosa 
- T1a-Tumour invades lamina propria or muscularis mucosa 
- T1b- Tumour invades submucosa 
T2 - Tumour invades muscularis propria 
T3 - Tumour penetrates subserosa without invasion of serosa 
T4 - Tumour invades serosa or adjacent structures 
- T4a- Tumour invades serosa 
-  T4b- Tumour invades adjacent structures 
N – Regional Lymph Nodes 
NX - Regional lymph nodes cannot be assessed 
N0 - No regional lymph node metastasis 
N1 - Metastasis in 1 to 2 regional lymph nodes 
N2 - Metastasis in 3 to 6 regional lymph nodes 
N3 - Metastasis in more than 7 regional lymph nodes 
M – Distant Metastasis 
MX - Distant metastasis cannot be assessed 
M0 - No distant metastasis 
M1 - Distant metastasis 
 
STAGE GROUPING 
Stage 0    Tis   N0   M0 
Stage IA    T1   N0   M0 
Stage IB    T1   N1   M0 
T2   N0   M0 
Stage IIA                            T1   N2   M0 
T2   N1   M0 
T3   N0   M0 
Stage IIB   T1  N3  M0 
    T2  N2  M0 
    T3  N1  M0 
Stage IIIA   T2  N3  M0 
    T3  N2  M0 
    T4a  N1  M0 
Stage IIIB   T2  N3  M0 
    T3  N2  M0 
    T4a  N1  M0 
Stage IIIC   T4a  N2  M0 
    T4b  N0  M0 
    T4b  N1  M0 
Stage IV   Any T  Any N  M1  
 
  
ANNEXURE IV 
IMMUNOHISTOCHEMISTRY PROCEDURE 
 
 
1. 4μ thick sections were cut from formalin fixed paraffin embedded 
tissue samples and transferred to gelatin-chrome alum coated slides. 
2. The slides were incubated at 58ºC for overnight. 
3. The sections were deparaffinized in xylene for 15 minutes x 2 changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes x 2 
changes. 
5. The sections were washed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 5 minutes. 
7. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with citrate buffer for 20 to 25 minutes. 
8. The slides were then cooled to room temperature and washed in 
running tap water for 5 minutes. 
9. The slides were then rinsed in distilled water for 5 minutes. 
10. Wash with appropriate wash buffer (phosphate buffer) for 5 minutes x 
2 changes. 
11. Apply peroxidase block over the sections for 10 minutes. 
12. Wash the slides in phosphate buffer for 5 minutes x 2 changes. 
13. Cover the sections with power block for 15 minutes. 
14. The sections were drained (without washing) and appropriate primary 
antibody was applied over the sections and incubated for 1 hour.  
15. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
16. The slides were covered with Super Enhancer for 30 minutes. 
17. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
18. The slides were covered with SS Label for 30 minutes. 
19. Wash in phosphate buffer for 5 minutes x 2 changes. 
20. DAB substrate was prepared by diluting 1 drop of DAB chromogen to 
1 ml of DAB buffer. 
21. DAB substrate solution was applied on the sections for 8 minutes. 
22. Wash with phosphate buffer solution for 5 minutes x 2 changes. 
23. The slides were washed well in running tap water for 5 minutes. 
24. The sections were counterstained with Hematoxylin stain for 2 
seconds (1 dip). 
25. The slides were washed in running tap water for 3 minutes. 
26. The slides are air dried, cleared with xylene and mounted with DPX. 
 ANNEXURE V 
SCORING SYSTEM FOR THE IMMUNOHISTOCHEMICAL 
MARKERS 
 
E Cadherin: 
3+:   preserved, continuous, linear, intercellular staining (similar to            
         that of  normal gastric mucosa) or densely dotted intercellular  
        staining in more  than 60% of all tumour cells;  
2+:   moderately reduced linear or dotted intercellular staining in  
        20-60% of all tumour cells;  
1+:   highly reduced, predominantly finely dotted intercellular  
        staining in less than 20% of all tumour cells;  
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S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
1 68/11 58 1 3 1 2  3 1 1            
2 155/11 70 1 3 3 1  3 1 2            
3 156/11 50 2 3 4 3  3 1 2            
4 164/11 63 1 1 3 3 4 1 2 3 2 1 Y Y Y Y      
5 241/11 45 1 3 1 1  5 2 3            
6 243/11 62 1 3 4 3  3 1 2            
7 357/11 40 1 3 4 1  3 1 2            
8 364/11 55 1 3 1 3  5 3 3            
9 367/11 60 1 3 4 3  5 2 3            
10 373/11 62 1 1 4 3 7 2 2 3 3 1 Y N N Y      
11 470/11 37 1 3 3 3  3 1 2            
12 484/11 60 1 3 4 2  3 1 1            
13 485/11 28 2 3 4 3  2 2 3            
14 556/11 56 2 3 4 3  3 1 3            
15 561/11 50 1 3 4 1  3 1 1            
16 563/11 40 1 3 4 2  5 2 3            
17 576/11 70 1 1 4 1 2 3 1 1 2 1 Y Y N N 1 1 Y 2 1 
18 617/11 45 1 3 3 1  3 1 2            
19 637/11 45 1 1 4 3 8 3 1 3 3 1 Y Y N Y      
20 702/11 61 1 3 3 3  3 1 2            
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
21 703/11 40 2 3 3 1  1 2 3            
22 742/11 64 1 3 4 2  3 1 1            
23 763/11 58 1 1 4 3 5 3 1 1 3 1 Y Y Y N 3 3 N 3 2 
24 798/11 60 1 3 1 2   3 1 2            
25 806/11 64 1 3 4 1  2 2 3            
26 992/11 60 1 3 5 4  3 1 1            
27 1051/11 84 2 3 1 3  3 1 1            
28 1053/11 65 2 3 4 3  3 3 3            
29 1126/11 54 1 3 2 1  3 1 2       2 1 Y 1 2 
30 1128/11 59 1 3 2 1  1 2 3            
31 1167/11 65 1 3 4 3  3 1 3            
32 1279/11 40 2 3 5 4  3 1 3       3 0 Y 3 2 
33 1306/11 49 1 1 4 3 3 3 1 1 3 1 N Y N Y 3 0 Y 0 1 
34 1355/11 75 1 1 4 2 3 3 1 2 3 1 Y Y Y N 3 2 Y 1 1 
35 1386/11 59 1 3 1 3  5 2 3            
36 1467/11 42 1 3 1 3  3 1 3       3 0 Y 3 2 
37 1473/11 65 1 3 4 3  3 1 1            
38 1474/11 75 1 3 3 1  3 1 2            
39 1480/11 21 2 3 3 1  1 2 3            
40 604/11 45 2 1 4 1 8 4 1 1 3 1 Y Y Y y 3 2 Y 3 2 
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
41 605/11 50 1 1 3 1 2 3 1 1 3 1 N N N N      
42 628/11 46 2 1 4 1 4 3 1 2 4 1 Y Y Y N 2 1 N 1 2 
43 638/11 60 1 3 3 1  3 1 2            
44 751/11 60 1 2 4 3 11 4 1 2 4 1 Y Y Y N      
45 780/11 55 1 3 4 3  1 2 3            
46 903/11 50 1 1 4 1 10 4 1 2 4 1 Y Y Y N      
47 959/11 50 2 3 3 3  2 2 3            
48 1062/11 55 1 1 4 1 4 3 1 2 4 1 Y Y N N      
49 1246/11 48 1 1 4 3 3 3 1 1 1 1 N N N N      
50 1362/11 55 1 3 4 2 4 1 2 3       0 0 N 0 1 
51 1418/11 70 1 1 4 3 3 3 1 2 3 1 Y N Y N 3 1 Y 1 1 
52 74/11 72 2 1 4 3 5 3 1 1 3 3 Y N Y N 3 0 Y 3 2 
53 101/11 60 1 1 4 3 4 3 1 2 3 1 Y N Y N 2 3 Y 1 2 
54 196/11 70 1 1 4 1 8 5 2 3 4 2 Y Y N N      
55 237/11 40 1 3 4 3  2 2 3            
56 327/11 65 1 1 4 1 5 5 2 3 3 1 N N N N      
57 352/11 38 2 1 4 3 4 3 1 2 3 1 Y N N N 3 3 Y 3 1 
58 522/11 62 1 1 4 3 3 3 1 2 4 1 Y Y N Y      
59 1486/11 40 2 2 3 3 9 3 1 3 3 2 Y N N N      
60 1536/11 51 2 3 2 3  1 2 3            
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
61 1603/11 52 1 3 1 1  3 1 2            
62 1604/11 62 2 3 4 3  4 1 2            
63 1607/11 65 1 3 4 3  3 1 2            
64 1608/11 56 1 3 4 3  4 1 1            
65 1613/11 63 1 3 4 3  4 2 3            
66 1617/11 35 2 3 4 3  3 1 2       2 0 Y 0 2 
67 1682/11 47 1 3 3 3  2 2 3            
68 1684/11 76 1 3 3 3  2 2 3            
69 1712/11 49 2 3 4 3  3 1 2       3 0 Y 0 2 
70 1759/11 70 1 3 4 3  3 1 2            
71 1761/11 45 1 3 3 3  3 1 2            
72 1871/11 35 1 3 4 3  3 1 2            
73 1950/11 60 1 3 4 3  3 1 2            
74 2017/11 65 1 3 3 1  2 2 3            
75 2048/11 62 2 1 4 3 3 3 1 2 2 1 Y Y N Y      
76 2071/11 65 1 3 4 3  3 1 1            
77 2190/11 44 2 3 4 1  2 2 3            
78 2215/11 47 1 3 4 3  3 1 2       2 2 Y 1 2 
79 2217/11 57 1 3 1 2  1 2 3            
80 2218/11 50 2 3 3 1  2 2 3            
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
81 2259/11 29 2 1 4 1 4 1 2 3 3 1 Y Y N N      
82 2339/11 70 2 3 4 3  1 2 3            
83 2382/11 70 1 3 3 3  3 1 1            
84 2426/11 55 2 3 4 3  3 1 1            
85 2512/11 55 1 3 3 1  2 2 3            
86 2518/11 50 2 3 4 3  4 1 2            
87 2591/11 55 1 3 3 3  3 1 2            
88 2592/11 50 2 3 4 3  3 1 2            
89 2593/11 47 1 3 3 1  3 1 2            
90 2662/11 52 1 3 4 3  5 2 3            
91 2732/11 42 1 3 3 3  1 2 3            
92 2862/11 55 1 3 4 3  3 1 1            
93 2865/11 40 2 3 3 3  5 2 3            
94 2959/11 70 1 3 4 3  2 2 3            
95 2965/11 50 1 3 3 3  2 2 3            
96 2967/11 60 2 3 5 5  2 2 3       0 0 Y 2 1 
97 3073/11 53 1 3 4 3  3 1 1       2 0 N 1 2 
98 3143/11 49 1 3 5 1  1 2 3            
99 3154/11 28 1 3 4 3  1 2 3            
100 3254/11 71 1 3 3 3  1 2 3            
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
101 3429/11 46 2 3 4 3  1 2 3            
102 3494/11 50 1 1 4 3 4 3 1 1 4 1 Y Y Y N N     
103 3502/11 65 1 3 4 3  3 1 1            
104 3505/11 72 1 3 4 3  3 1 2            
105 3506/11 40 1 3 4 3  1 2 3            
106 3747/11 58 1 3 3 1  1 2 3            
107 3767/11 50 1 3 1 3  2 1 2            
108 3768/11 55 1 3 1 3  3 1 1            
109 3771/11 55 1 3 4 3  3 1 1            
110 3774/11 50 2 3 2 1  1 2 3            
111 3813/11 54 1 1 4 3 2 3 1 3 4 1 Y Y N Y      
112 3849/11 32 1 3 3 3  2 1 2            
113 3874/11 45 2 3 3 2  3 1 2            
114 3902/11 35 1 3 3 3  1 2 3            
115 3903/11 42 1 3 4 3  1 2 3            
116 3905/11 45 1 3 3 3  2 2 3            
117 3928/11 58 1 3 2 3  2 2 3            
118 1658/11 52 1 2 2 3 3 3 1 3 3 1 Y Y N N 3 0 Y 3 2 
119 1691/11 46 2 1 4 1 4 3 1 2 4 1 Y Y Y N      
120 1842/11 27 2 1 4 2 5 3 1 3 4 1 Y Y N Y      
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
121 1861/11 57 1 1 4 3 5 3 1 3 3 1 Y Y Y N 0 0 N 2 2 
122 2468/11 60 1 1 4 1 4 3 1 2 4 1 Y Y N N      
123 3080/11 35 2 3 4 3  3 1 1            
124 3279/11 50 2 2 1 3 5 1 2 3 4 1 Y Y N N 3 0 N 2 1 
125 3426/11 42 2 3 2 3  1 2 3            
126 3428/11 48 1 3 4 3  1 2 3            
127 3430/11 60 1 3 4 2  3 1 2       0 0 N 1 2 
128 3432/11 32 2 3 3 3  3 1 2            
129 3457/11 54 1 1 4 3 7 1 2 3 3 1 Y Y Y N      
130 3459/11 56 1 3 3 1  2 1 2            
131 3538/11 62 1 3 4 1  3 1 1            
132 3585/11 71 1 2 3 3 3 3 1 2 2 1 Y Y N N      
133 3623/11 60 1 1 4 3 3 1 2 3 4 1 Y Y Y N      
134 3670/11 62 1 1 4 1 4 3 1 2 3 1 Y N N N      
135 3914/11 50 1 2 3 3 9 5 2 3 3 1 Y Y Y N 0 0 N 3 1 
136 2972/11 60 2 2 5 5 12 1 2 3 4 1 Y Y Y N 0 0 N 0 2 
137 2836/11 50 1 1 4 1 3 3 1 1 3 1 Y Y N Y 3 0 Y 0 1 
138 3968/11 46 1 3 4 3  2 2 3            
139 3970/11 28 1 3 4 3  1 2 3            
140 3977/11 32 1 3 4 3  2 2 3       0 0 Y 0 1 
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
141 4039/11 56 1 3 4 2  3 1 2            
142 4040/11 40 2 3 4 3  1 2 3            
143 4042/11 60 1 3 4 3  3 1 2            
144 4140/11 57 1 3 4 1  3 1 1            
145 4337/11 60 2 3 4 3  2 2 3       0 3 N 1 2 
146 4359/11 70 1 3 3 1  4 1 1            
147 4389/11 58 1 3 4 1  3 1 1            
148 4425/11 35 1 3 4 3  3 1 1       2 0 Y 1 2 
149 4486/11 40 1 3 4 3  1 2 3            
150 994/11 64 1 3 2 3  3 1 2       2 3 N 0 2 
151 487/11 60 1 3 5 4  1 2 3            
152 4086/11 39 2 3 4 1  3 1 2       3 2 N 3 2 
153 4090/11 60 2 3 4 3  3 1 2       3 0 Y 3 2 
154 4144/11 62 1 3 3 3  3 1 2            
155 4214/11 47 1 3 4 3  3 1 2            
156 4312/11 70 2 3 2 1  1 2 3       0 0 Y 0 2 
157 4589/11 75 1 3 4 3  3 1 2            
158 4685/11 39 1 3 4 1  3 1 3            
159 4804/11 60 1 1 4 3 3 3 1 1 3 1 Y Y N N      
160 4821/11 41 1 3 1 2  1 2 3            
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
161 4822/11 56 1 3 3 1  1 2 3            
162 4865/11 46 2 3 1 3  1 2 3            
163 4850/11 48 1 1 3 1 4 1 2 3 3 1 Y Y N Y      
164 4890/11 75 1 3 4 2  3 1 1            
165 4940/11 80 1 3 4 3  2 2 3            
166 4941/11 68 1 3 4 3  3 1 2            
167 4975/11 60 1 3 4 3  2 2 3            
168 4978/11 40 2 3 4 3  2 2 3            
169 4979/11 47 1 3 3 2  3 1 3            
170 5019/11 40 1 1 4 1 4 3 1 2 3 1 Y Y N Y      
171 5065/11 36 2 3 4 3  3 1 2            
172 5093/11 60 2 1 4 3 7 5 2 3 3 1 Y Y Y N 3 0 Y 1 1 
173 5121/11 70 1 3 3 2  3 1 1            
174 5144/11 67 1 3 4 3  3 1 1            
175 5195/11 53 1 3 1 3  3 1 3            
176 5198/11 70 1 3 4 3  1 2 3            
177 5202/11 58 1 3 1 2  1 2 3            
178 5222/11 70 2 3 4 2  2 2 3            
179 5266/11 50 1 3 3 1  1 2 3            
180 5337/11 50 1 3 4 3  2 2 3            
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
181 5384/11 62 1 1 4 2 5 2 2 3 3 1 Y Y N Y 3 2 N 0 1 
182 5396/11 54 1 3 4 2  3 1 2            
183 5397/11 54 1 3 4 2  3 1 2            
184 5398/11 50 1 3 1 3  1 2 3       2 0 N 0 2 
185 5482/11 52 1 3 4 3  1 2 3            
186 5484/11 52 1 3 4 3  2 2 3            
187 5485/11 68 1 3 3 3  3 1 2            
188 5497/11 67 1 1 4 1 2 3 1 2 4 1 Y Y N Y      
189 5520/11 60 1 3 4 2  3 1 2            
190 5571/11 65 1 3 4 3  3 1 1            
191 5628/11 68 1 1 4 3 5 3 1 2 3 1 Y N N Y      
192 5638/11 64 1 3 1 3  3 1 1            
193 5650/11 23 2 3 4 2  2 2 3            
194 5753/11 53 1 3 4 2  3 1 1            
195 5823/11 52 1 3 4 3  3 1 2            
196 5839/11 43 1 3 3 1  1 2 3            
197 5890/11 52 1 3 3 1  1 2 3            
198 4352/11 45 1 1 4 3 3 1 2 3 4 1 Y Y N N      
199 4385/11 60 1 3 4 3  1 2 3            
200 4533/11 45 1 2 3 1 4 3 1 1 4 1 Y Y Y N      
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
201 4545/11 55 1 1 3 3 5 3 1 2 4 1 Y Y Y N      
202 4675/11 55 1 1 4 1 5 5 2 3 4 1 Y N N Y      
203 4701/11 70 2 1 4 1 9 1 2 3 2 1 Y Y N N      
204 5016/11 39 1 1 4 1 4 3 1 2 4 3 Y Y Y N      
205 5064/11 60 1 3 4 3  1 2 3            
206 5273/11 47 2 1 4 3 2 5 2 3 4 1 Y N Y N      
207 5295/11 46 1 1 4 3 4 3 1 1 1 1 N N N N      
208 5631/11 67 1 3 4 3  3 1 3       0 0 N 0 2 
209 5885/11 52 1 1 4 3 5 5 2 3 2 1 N N N N 2 2 Y 1 1 
210 6197/11 48 1 1 4 1 3 3 1 2 3 1 N N Y Y      
211 6585/11 51 1 3 4 1  1 2 3            
212 6696/11 50 1 3 1 1  1 2 3            
213 7061/11 59 1 3 4 3  4 1 1            
214 7183/11 60 2 2 3 3 6 3 1 1 4 1 Y Y Y N      
215 7599/11 58 1 1 4 3 11 3 1 2 4 3 Y N N N      
216 5978/11 75 1 3 4 3  3 1 2            
217 5991/11 65 1 1 4 3 7 3 1 2 4 1 N N Y Y 3 2 N 0 1 
218 6033/11 44 1 3 1 1  3 1 1            
219 6036/11 80 1 3 4 3  1 2 3            
220 6037/11 34 1 3 4 1  1 2 3            
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
221 6038/11 70 1 3 4 3  3 1 3            
222 6060/11 61 1 1 4 1 4 1 2 3 3 1 Y Y N N 2 0 N 1 2 
223 6140/11 45 2 3 5 4  2 2 3       0 0 N 1 2 
224 6144/11 50 2 3 5 5  2 2 3            
225 6185/11 65 1 3 3 3  3 1 1            
226 6230/11 45 2 3 1 3  1 2 3            
227 6270/11 58 1 3 5 5  3 1 1            
228 6405/11 69 1 3 5 3  3 1 1            
229 6411/11 75 1 1 4 2 4 3 1 2 2 1 N N N Y 3 1 N 1 1 
230 6454/11 60 1 3 4 3  3 1 1            
231 6568/11 64 1 3 1 3  1 2 3            
232 6599/11 53 1 1 4 2 3 3 1 1 1 1 N N N Y      
233 6733/11 43 1 3 4 3  1 2 3            
234 6818/11 40 2 2 1 3 5 4 1 1 2 1 Y Y N N      
235 6991/11 52 1 3 4 3  3 1 2            
236 6992/11 60 1 3 4 3  1 2 3            
237 6994/11 28 2 3 4 1  2 2 3            
238 7033/11 72 1 3 4 3  1 2 3            
239 7170/11 60 1 2 5 5 12 1 2 3 4 1 Y Y Y N      
240 7224/11 50 2 2 5 5 15 3 1 2 2 1 Y N N N      
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
241 7279/11 50 2 3 3 3  1 2 3            
242 7281/11 78 1 3 4 3  3 1 2            
243 7282/11 38 2 3 4 1  3 1 2            
244 7316/11 58 1 3 3 3  5 2 3            
245 7330/11 34 1 1 4 1 2 1 2 3 3 1 N N N Y      
246 7427/11 56 2 3 1 3  2 2 3            
247 7433/11 57 1 3 3 3  3 1 2            
248 7459/11 51 1 3 4 3  3 1 2            
249 7563/11 65 1 3 1 3  3 1 2            
250 7564/11 80 2 3 4 3  3 1 3            
251 7566/11 54 1 3 4 3  3 1 3            
252 7619/11 78 1 2 4 3 3 3 1 1 3 1 Y Y N Y      
253 7658/11 45 1 3 1 3  2 2 3            
254 7662/11 59 1 3 1 3  4 1 1            
255 7725/11 31 2 1 4 1 3 3 1 2 3 1 Y N N Y      
256 7850/11 62 1 3 4 3  3 1 1            
257 7851/11 64 1 3 4 3  1 2 3            
258 7854/11 42 1 3 4 3  1 2 3       0 0 N 1 2 
259 7898/11 70 1 3 4 3  3 1 3            
260 7965/11 60 1 1 4 3 5 3 1 2 4 1 Y N N Y 3 3 N 0 1 
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
261 7978/11 59 1 3 3 1  3 1 2            
262 7996/11 60 2 3 2 3  3 1 2       0 0 Y 1 2 
263 7997/11 65 2 3 4 3  3 1 3       1 0 N 1 2 
264 8004/11 70 1 3 4 3  3 1 2            
265 8005/11 51 2 3 1 3  3 1 1       1 0 y 0 1 
266 8037/11 70 1 1 4 3 4 3 1 2 2 1 Y N N Y      
267 8189/11 55 2 3 4 3  3 1 2            
268 8225/11 60 1 2 5 5 15 3 1 2 3 4 Y Y Y N      
269 8242/11 65 2 3 5 5  1 2 3            
270 8245/11 78 2 3 4 3  3 1 3            
271 8270/11 65 2 3 4 3  3 1 3       2 0 Y 0 2 
272 8271/11 60 2 3 4 3  2 2 3            
273 8272/11 50 1 3 3 3  1 2 3            
274 8288/11 40 1 3 4 3  3 1 2            
275 8318/11 58 2 1 4 3 2 3 1 2 3 1 Y N N Y      
276 8356/11 70 1 1 4 2 5 5 2 3 3 1 Y Y N Y      
277 8490/11 55 1 1 4 2 4 3 1 2 2 1 Y N N N      
278 8528/11 55 2 1 4 3 3 3 1 2 3 1 Y N N Y      
279 8558/11 55 1 3 3 2  2 2 3            
280 8329/11 53 2 3 3 4  3 1 1            
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
281 8332/11 75 2 1 4 1 3 3 1 3 2 1 N N N N      
282 8381/11 60 2 3 4 3  1 2 3            
283 8500/11 60 2 1 4 1 6 1 2 3 3 1 Y N N Y      
284 8603/11 70 1 3 4 1  2 2 3            
285 8699/11 64 1 3 1 1  3 1 2            
286 9015/11 42 2 3 4 1  2 2 3            
287 9033/11 70 2 3 1 3  3 1 3            
288 9060/11 65 1 3 4 3  3 1 3            
289 9138/11 47 2 3 3 3  3 1 3            
290 9331/11 40 1 3 4 1  5 2 3            
291 9341/11 52 1 3 3 3  2 2 3            
292 9394/11 65 1 3 3 3  3 1 2            
293 9426/11 60 1 3 4 3  3 1 1            
294 9510/11 52 2 1 4 1 2 3 1 2 3 1 N N N Y      
295 9604/11 60 1 2 4 1 6 3 1 3 3 1 Y Y Y N      
296 9626/11 64 1 3 3 3  3 1 2            
297 9687/11 60 1 2 1 3 8 3 1 2 2 1 N N N Y      
298 9729/11 35 1 2 5 5 15 1 2 3 3 2 Y Y Y Y 3 1 Y 0 1 
299 9753/11 32 1 3 4 1  3 1 2            
300 9761/11 55 1 3 3 1  4 1 2            
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
301 9785/11 45 2 3 4 1  4 1 1            
302 9787/11 50 1 2 3 1 2 3 1 1 2 1 N N N N      
303 9885/11 29 2 3 2 2  1 2 3            
304 9886/11 22 2 3 4 3  3 1 1            
305 9890/11 70 2 3 4 2  4 1 2            
306 9918/11 63 1 3 3 1  3 1 2            
307 9941/11 68 2 3 4 3  3 1 2            
308 9942/11 55 1 3 4 2  3 1 1            
309 9994/11 55 1 3 1 1  3 1 2            
310 10044/11 85 1 3 4 3  3 1 3            
311 10060/11 55 1 3 3 1  3 1 2            
312 10094/11 60 1 3 4 1  3 1 2            
313 10096/11 73 1 3 4 3  3 1 1            
314 10148/11 64 1 2 2 3 5 1 2 3 4 1 Y Y N Y      
315 10197/11 73 1 3 4 3  3 1 3            
316 10198/11 39 1 3 4 3  2 2 3            
317 10212/11 75 1 3 4 1  3 1 2            
318 10214/11 55 2 3 1 3  2 2 3            
319 10242/11 74 1 3 4 1  3 1 3            
320 10284/11 48 1 3 4 3  3 1 2            
S.No HPE No Age Sex Proc Site Gross Dia Hist type Lauren Grade Depth Margin LI VI PNI Lymp E Cad EGFR p53 Her2/neu Follow up 
312 10306/11 62 1 3 3 1  4 1 1            
322 10343/11 41 1 3 4 3  3 1 3            
323 10351/11 61 1 3 3 2  5 2 3            
324 10352/11 67 2 3 4 1  3 1 2            
325 7776/11 52 2 3 4 3  3 1 2            
326 8023/11 54 1 1 4 1 6 3 1 2 3 1 Y Y N N      
327 8100/11 54 2 2 4 2 2 3 1 2 2 1 N N N N      
328 8197/11 40 2 3 1 3  2 2 3            
329 8764/11 55 1 1 4 1 9 5 2 3 4 1 Y N N N      
330 8896/11 37 2 1 4 3 5 1 2 3 4 1 Y Y Y Y 1 0 N 0 1 
331 8897/11 53 1 1 4 3 5 3 1 2 4 1 N N N Y      
332 9010/11 50 1 1 3 2 2 3 1 1 2 1 N N N Y      
333 9212/11 56 1 1 4 1 5 3 1 2 4 1 Y Y Y N      
334 9537/11 52 1 1 4 1 6 2 2 3 2 1 Y Y Y N      
335 9632/11 21 1 3 4 1  3 1 2            
336 9755/11 70 1 2 2 3 8 3 1 2 4 1 Y Y N Y      
337 9812/11 68 2 1 4 3 3 1 2 3 3 1 Y N N N      
338 10147/11 55 2 3 2 1  3 1 2            
 
KEY TO MASTER CHART: 
Age: 
     -Entered in Years 
Sex: 
     1- Male, 2- Female 
Proc (Procedure done):  
     Subtotal Gastrectomy, 2- Total 
gastrectomy, 3- Endoscopic Biopsy 
Site: 
     1-EsoCardia, 2-Fundus, 3-Body,                           
4-Pyroloantrum, 5- Pangastric 
Gross: 
     1-Ulcerative, 2-Nodular,                 
3-Ulceroproliferative, 4-Linitis plastica 
Dia (Maximum dimension of 
Tumour)  
     -Entered in centimetres 
Hist (Histological subtype) 
    1- Diffuse, 2- Signet ring cell type, 
3- Tubular, 4- Papillary, 5- Mucinous 
Lauren (Lauren’s classification) 
     1-Intestinal type, 2-Diffuse type,                                   
3-Indeterminate 
Grade 
     1-Well differentiated, 2-moderately 
differentiated, 3- poorly differentiated 
Depth (Depth of infiltration) 
     1-T1, 2-T2, 3-T3, 4-T4 
 
 
Margin (Surgical resected Margin): 
   1-Both margins free, 2-proximal 
margin involved, 3-distal margin 
involved, 4- Both margins involved  
 LI (Lymphatic invasion): 
   Y – Present, N- Absent 
VI (Vascular Invasion): 
    Y – Present, N- Absent 
PNI ( Perineural Invasion): 
    Y – Present, N- Absent 
Lymp (Lymphocytic response): 
    Y – Present, N- Absent 
E Cad ( E Cadherin):  
    0 - 0,   1-1+   ,2-2+,  3-3+ 
EGFR: 
      0 - 0,   1-1+   ,2-2+,  3-3+ 
P53: 
      y- Positive, N-Negative 
HER-2/Neu: 
     0 - 0,   1-1+   ,2-2+,  3-3+ 
Follow up: 
   1- Alive, 2- Dead 
 
 
 
 
 
 
ABSTRACT 
AIM: 
The variable prognosis of gastric cancer within a pathological stage necessitates 
the identification of subgroups of patients with a more aggressive disease. The role 
of E Cadherin, EGFR, p53 and HER-2/Neu expression in gastric carcinoma is far 
from being fully established. The aim of the present study was to identify the 
incidence and distribution of gastric carcinoma in patients admitted in the 
Government General Hospital, Chennai in the year 2011 and to evaluate the 
expression of E Cadherin, EGFR, p53 and HER-2/Neu in gastric cancer and 
correlate the findings with several clinico-pathological features, prognosis and 
survival. 
MATERIALS AND METHODS: 
Formalin-fixed paraffin-embedded tissue samples from 50 cases (25 endoscopic 
biopsies and 25 gastric resection specimens) of gastric carcinoma in the year 2011 
were studied by immunohistochemistry, using monoclonal antibodies to E 
Cadherin, EGFR, p53 and HER-2/Neu. The results were correlated with clinico-
pathological features and survival. 
RESULTS: 
Reduced expression of E Cadherin was significantly associated with reduced 
survival. Increase in number of cases with reduced E Cadherin expression was seen 
with Lauren’s intestinal type, poorly differentiated grade, presence of lymphatic 
invasion and absence of lymphocytic response. A statistically significant 
association was found between EGFR expression and moderately differentiated 
grade of tumour. Increase in the number of cases with EGFR over expression was 
seen with tubular type of carcinoma, Lauren’s intestinal type and absence of 
vascular invasion. Increase in frequency of cases with p53 positivity was seen with 
tubular type, Lauren’s intestinal type, moderately and poorly differentiated grades 
and T3 level of infiltration. A significant association was found between HER-
2/Neu over expression and absence of lymphocytic response in the adjacent foci of 
tumour. Increase in number of cases with HER-2/Neu over expression was found 
to be associated with female sex, Lauren’s intestinal type and T3 level of 
infiltration. 
CONCLUSION:  
The role played by cell proliferation in the growth and aggressiveness of gastric 
tumours is complex and still not clarified. Study of the expression of E Cadherin, 
EGFR, p53 and HER-2/Neu in gastric carcinoma could be useful as independent 
prognostic markers in identification of patients at high risk of recurrence and poor 
survival. Follow up of these patients for 5 more years could throw more light on 
the role of the above mentioned markers as long term prognostic indicators. 
 
 
